<SEC-DOCUMENT>0001193125-21-159238.txt : 20210512
<SEC-HEADER>0001193125-21-159238.hdr.sgml : 20210512
<ACCEPTANCE-DATETIME>20210512170220
ACCESSION NUMBER:		0001193125-21-159238
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20210512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210512
DATE AS OF CHANGE:		20210512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		21915966

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d31397d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;12, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>VIRACTA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-51531</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-3295878</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Identification No.)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>2533 S Coast Hwy 101, Suite 210</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Cardiff, California</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>92007</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (858)
<FONT STYLE="white-space:nowrap">400-8470</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.0001 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>VIRX</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2021, Viracta Therapeutics, Inc. (the &#147;Company&#148;) issued a press release announcing its financial results for the
fiscal quarter ended March&nbsp;31, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the information furnished in this Item 2.02 and the press release attached hereto as Exhibit 99.1 shall not be deemed to be
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company announcing its first quarterly financial results since completing the merger between Sunesis Pharmaceuticals
Inc. and Viracta Therapeutics, Inc., the Company is providing disclosure regarding the business of the combined company. The disclosure is filed herewith as Exhibit 99.2, and such disclosure is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d) Exhibits </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d31397dex991.htm">Press Release, dated May&nbsp;12, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d31397dex992.htm">Business Section of Viracta Therapeutics, Inc. </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;12, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Chevallard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel Chevallard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Operating Officer and Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d31397dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g31397g0512204731096.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate
Updates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">NAVAL-1,</FONT> a global pivotal trial for the treatment of relapsed/refractory <FONT
STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma is on track to be initiated in Q2 2021 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">NAVAL-1</FONT> trial design to be featured in a Key Opinion Leader webinar taking place on May&nbsp;20,
2021 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Closed merger with Sunesis Pharmaceuticals and $65&nbsp;million private placement </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cash and cash equivalents of approximately $129.2&nbsp;million as of March&nbsp;31, 2021 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PR Newswire, San Diego, May</I><I></I><I>&nbsp;12, 2021 &#150; </I><U>Viracta</U> Therapeutics, Inc. (Viracta or the Company), a precision oncology company
targeting virus-associated malignancies, today announced financial results for the first quarter of 2021 and provided a clinical and corporate update. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Viracta has emerged from our first quarter as a publicly traded company well-positioned to make a significant impact on patients and create meaningful
value for our shareholders. We are on track to initiate our pivotal <FONT STYLE="white-space:nowrap">NAVAL-1</FONT> trial as planned this quarter for the treatment of <FONT STYLE="white-space:nowrap">EBV-associated</FONT> lymphoma, and we look
forward to expanding into our second global clinical program in <FONT STYLE="white-space:nowrap">EBV-associated</FONT> solid tumors in the second half of 2021,&#148; said Ivor Royston, M.D., President and Chief Executive Officer of Viracta. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Royston continued, &#147;Today, we are excited to provide additional details of the <FONT STYLE="white-space:nowrap">NAVAL-1</FONT> trial design,
which has been reviewed by the United States Food and Drug Administration. We believe the innovative and adaptive design of this registration-enabling pivotal trial will allow us to simultaneously progress towards potential NDA filings in multiple
lymphoma subtypes.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>First Quarter 2021 and Recent Highlights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Announced design of <FONT STYLE="white-space:nowrap">NAVAL-1,</FONT> a global pivotal trial in Epstein-Barr
virus (EBV)-positive relapsed/refractory (R/R) lymphoma.</B> <FONT STYLE="white-space:nowrap">NAVAL-1</FONT> (<B>Na</B>natinostat in Combination with <B>Val</B>ganciclovir) is a multinational, multicenter, open-label Phase 2 basket trial. The trial,
which will include multiple subtype-specific cohorts of R/R <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma patients, is designed to evaluate the anti-tumor activity of the combination treatment of nanatinostat with valganciclovir and
is anticipated to enroll up to 140 patients. The primary endpoint of the trial is objective tumor response rate as assessed by an independent review committee. If successful, Viracta believes this trial could support multiple NDA filings across
various <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma subtypes. Viracta remains on track to initiate <FONT STYLE="white-space:nowrap">NAVAL-1</FONT> in Q2 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Completed enrollment in Phase 2 expansion cohort of its Phase 1b/2 R/R
<FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma trial, with updated data expected in H2 2021. </B><FONT STYLE="white-space:nowrap">VT3996-201,</FONT> Viracta&#146;s Phase 1b/2 open-label, dose escalation/expansion trial of
nanatinostat-valganciclovir combination treatment in R/R <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma has generated promising efficacy and safety data to date, as presented at the
62<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> American Society of Hematology Annual Meeting in December 2020, including preliminary objective response and complete response rates (ORR/CR) of 80%/40% (n=10) and 67%/33% (n=6) in T/NK cell <FONT
STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma and diffuse large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma, respectively. The median duration of response was 10.4 months. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Closed merger with </B><B>Sunesis</B><B> Pharmaceuticals, Inc. </B>Shares of the combined company, Viracta
Therapeutics, Inc., commenced trading on the Nasdaq Global Select Market under the ticker symbol &#147;VIRX&#148; on February&nbsp;25, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Completed a $65</B><B></B><B>&nbsp;million private placement. </B>On February&nbsp;24, 2021, Viracta closed a
private financing featuring a premier investor syndicate of biotechnology-focused and institutional accredited investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strengthened balance sheet through a multi-license milestone and royalty monetization transaction with XOMA.
</B>In March 2021, Viracta announced that XOMA had purchased the potential future milestones and royalties associated with existing licenses relating to two clinical-stage drug candidates that Viracta obtained in the merger in exchange for an
upfront payment of $13.5&nbsp;million and up to $20&nbsp;million in a <FONT STYLE="white-space:nowrap">pre-commercialization,</FONT> event-based milestone. <B></B>In the merger, Viracta also obtained exclusive and global rights to assets previously
held by Sunesis including <FONT STYLE="white-space:nowrap">SNS-510,</FONT> a <FONT STYLE="white-space:nowrap">PDK-1</FONT> inhibitor, and vecabrutinib, a BTK inhibitor. Viracta is evaluating future development and collaboration opportunities for <FONT
STYLE="white-space:nowrap">SNS-510</FONT> and potential partnering opportunities for vecabrutinib. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Extended intellectual property protection around lead lymphoma program. </B>In March 2021, the U.S. Patent and
Trademark Office (USPTO) granted patent 10,953,011, which covers the anticipated dose regimen to be advanced in the <FONT STYLE="white-space:nowrap">NAVAL-1</FONT> trial. The patent provides Viracta with intellectual property protection into at
least 2040. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strengthened company leadership with new appointments to the Board of Directors and management team.
</B>Throughout the first quarter, Viracta appointed the following life sciences industry veterans to the Board of Directors: Stephen Rubino, Ph.D., MBA, and Barry J. Simon, M.D., who were each appointed following the closing of the merger, Thomas
Darcy, who was appointed in connection with the closing of the merger, and Nicole Onetto, M.D., who remained on the combined company&#146;s Board of Directors following the merger. The Company also appointed Cheryl A. Madsen, RAC as Senior Vice
President, Regulatory Affairs. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anticipated 2021 Milestones </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of <FONT STYLE="white-space:nowrap">NAVAL-1,</FONT> a global Phase 2 pivotal trial for R/R <FONT
STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma: Q2 2021 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clearance of IND for a Phase 1b/2 clinical trial in <FONT STYLE="white-space:nowrap">EBV-positive</FONT> solid
tumors: <FONT STYLE="white-space:nowrap">mid-2021</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiation of a global Phase 1b/2 clinical trial in <FONT STYLE="white-space:nowrap">EBV-positive</FONT> solid
tumors: H2 2021 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Updated data from Phase 1b/2 trial in R/R <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma <FONT
STYLE="white-space:nowrap">(VT3996-201):</FONT> H2 2021 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>First Quarter 2021 Financial Results </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash Position &#150; </B>Cash and cash equivalents totaled approximately $129.2&nbsp;million as of
March&nbsp;31, 2021. Viracta expects to end 2021 with greater than $100&nbsp;million in cash and cash equivalents, which it expects will be sufficient to fund its operations into 2024. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Research and Development Expenses &#150; </B>Research and development expenses were $4.0&nbsp;million for the
quarter ending March&nbsp;31, 2021, compared to $3.4&nbsp;million for the same period in 2020. This increase was primarily due to costs incurred to support study initiation activities for <FONT STYLE="white-space:nowrap">NAVAL-1,</FONT> in addition
to an increase in headcount and <FONT STYLE="white-space:nowrap">non-cash</FONT> share-based compensation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>General and Administrative Expenses &#150; </B>General and administrative expenses were $3.8&nbsp;million for
the quarter ending March&nbsp;31, 2021, compared to $1.0&nbsp;million for the same period in 2020. This increase was primarily due to <FONT STYLE="white-space:nowrap">non-recurring,</FONT> merger-related costs of approximately $2.0&nbsp;million
incurred in the period, in addition to incremental costs associated with being a publicly traded company and <FONT STYLE="white-space:nowrap">non-cash</FONT> share-based compensation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development &#150; </B><FONT
STYLE="white-space:nowrap">Non-recurring,</FONT> <FONT STYLE="white-space:nowrap">non-cash</FONT> operating expenses of $84.5&nbsp;million associated with the <FONT STYLE="white-space:nowrap">write-off</FONT> of
<FONT STYLE="white-space:nowrap">in-process</FONT> research and development acquired in the merger were recorded for the quarter ending March&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Gain on Royalty Purchase Agreement</B><I> </I><B>&#150;</B><I> </I>Gain on Royalty Purchase Agreement for the
quarter ended March&nbsp;31, 2021 was associated with upfront proceeds of $13.5&nbsp;million received in connection with the multi-license milestone and royalty monetization transaction with XOMA Corporation in March 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Adjusted income or loss from operations</B> &#150; Adjusted income from operations for the quarter ended
March&nbsp;31, 2021, excluding the <FONT STYLE="white-space:nowrap">non-recurring</FONT> and <FONT STYLE="white-space:nowrap">non-cash</FONT> operating expenses associated with the <FONT STYLE="white-space:nowrap">write-off</FONT> of <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development acquired in the merger (a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> measure) was $5.6&nbsp;million, compared to an unadjusted loss from operations of $78.8&nbsp;million.
There is not a comparative adjustment to loss from operations for the same period in 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Net loss &#150; </B>Net loss was $79.2&nbsp;million, or $5.22 per share (basic and diluted) for quarter ended
March&nbsp;31, 2021, compared to $4.4&nbsp;million, or $1.86 per share (basic and diluted), for the same period in 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Opinion
Leader Webinar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The design of <FONT STYLE="white-space:nowrap">NAVAL-1,</FONT> a global pivotal trial in
<FONT STYLE="white-space:nowrap">EBV-positive</FONT> R/R lymphoma will be discussed during a Key Opinion Leader webinar on May&nbsp;20, 2021 at 2pm EST. The webinar will feature presentations by Pierluigi Porcu, M.D. (Thomas Jefferson University)
and Kristen Cunanan, Ph.D. (Stanford University School of Medicine), who will discuss the current treatment landscape, unmet medical need in <FONT STYLE="white-space:nowrap">EBV-associated</FONT> lymphoma and the trial design of <FONT
STYLE="white-space:nowrap">NAVAL-1.</FONT> The formal presentations will then be followed by a Q&amp;A session with Drs. Porcu and Cunanan, accompanied by Company management. A link to register for the webcast is here:
<U>https://media.rampard.com/202105203/</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">NAVAL-1</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NAVAL-1</FONT> (<B>Na</B>natinostat in Combination with <B>Val</B>ganciclovir) is a registration-enabling multinational,
multicenter, open-label Phase 2 basket trial. The trial will include multiple subtype-specific with various <FONT STYLE="white-space:nowrap">EBV-positive</FONT> relapsed/refractory lymphoma and is anticipated to enroll up to 140 patients. The
primary endpoint of the trial is objective tumor response rate, while secondary endpoints include duration of response, survival outcomes, and the safety profile of the combined treatment. Trial eligibility includes patients with <FONT
STYLE="white-space:nowrap">EBV-positive</FONT> R/R lymphoma following two or more prior systemic therapies with no available standard therapies. For ENKTL patients only, eligibility includes patients with R/R disease following one or more prior
systemic therapies with no available standard therapies who have failed an asparaginase-containing regimen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Viracta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Viracta is a precision oncology company targeting virus-associated malignancies. Viracta&#146;s proprietary investigational drug, nanatinostat, is currently
being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma. Viracta is pursuing application of this inducible
synthetic lethality approach in other <FONT STYLE="white-space:nowrap">EBV-associated</FONT> malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information please visit&nbsp;<U>www.viracta.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains
&#147;forward-looking&#148; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: being on track for initiation and the details and timeline for the <FONT
STYLE="white-space:nowrap">NAVAL-1</FONT> trial and the <FONT STYLE="white-space:nowrap">EBV-associated</FONT> solid tumor trial and related expectations; the ability of Viracta to simultaneously advance multiple NDA filings from the <FONT
STYLE="white-space:nowrap">NAVAL-1</FONT> trial; the timing of the clearance of the IND for the solid tumor trial and the updated date from the ongoing Phase1b/2 trial; the sufficiency of the Company&#146;s cash and cash equivalents to fund
operations into 2024; Viracta&#146;s ability to value for its shareholders; and other statements that are not historical facts.&nbsp;Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed
or implied in any forward-looking statement include, but are not limited to: Viracta&#146;s ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta&#146;s plans to develop and commercialize its
product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta&#146;s planned clinical trials; the timing of the availability of data from Viracta&#146;s clinical trials; previous
preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta&#146;s plans to research, develop and commercialize its current and
future product candidates; the clinical utility, potential benefits and market acceptance of Viracta&#146;s product candidates; Viracta&#146;s ability to identify additional products or product candidates with significant commercial potential;
developments and projections relating to Viracta&#146;s competitors and its industry; the impact of government laws and regulations; Viracta&#146;s ability to protect its intellectual property position; and Viracta&#146;s estimates regarding future
expenses, capital requirements and need for additional financing in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These risks and uncertainties may be amplified by the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional
These risks and uncertainties may be amplified by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual
results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking
statements are included under the caption &#147;Risk Factors&#148; and elsewhere in Viracta&#146;s reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at&nbsp;<U>www.sec.gov</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update
these forward-looking statements, except as required by law or applicable regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT>
Financial Measures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our results reported in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;), we believe
certain <FONT STYLE="white-space:nowrap">non-GAAP,</FONT> or adjusted, measures are useful in evaluating our operating performance. We use adjusted financial measures to evaluate our ongoing operations and for internal planning and forecasting
purposes. We believe that adjusted financial measures, when taken collectively, may be helpful to investors because they can provide consistency and comparability with past financial performance. However, adjusted financial information has
limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In particular, other companies, including companies in our industry, may calculate
similarly titled <FONT STYLE="white-space:nowrap">non-GAAP</FONT> or adjusted measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our adjusted financial measures as tools for
comparison. A reconciliation is provided below for adjusted financial measures to the most directly comparable financial measure stated in accordance with U.S. GAAP. Investors are cautioned that there are a number of limitations associated with the
use of <FONT STYLE="white-space:nowrap">non-GAAP,</FONT> or adjusted, financial measures as analytical tools. Investors are encouraged to review the related U.S. GAAP financial measures and the reconciliation of these adjusted financial measures to
their most directly comparable U.S. GAAP financial measure, and not to rely on any single financial measure to evaluate our business. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investor Relations Contact:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Company Contact:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joyce Allaire</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dan Chevallard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LifeSci Advisors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>jallaire@lifesciadvisors.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>dchevallard@viracta.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">915-2569</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(858) <FONT STYLE="white-space:nowrap">771-4193</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOURCE Viracta Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Viracta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selected Balance Sheet Highlights </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B><I>(Unaudited)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 11,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Viracta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands except share and per share data) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Unaudited) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three Months Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on Royalty Purchase Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (79,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (4,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (5.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (1.86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,166,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,373,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Viracta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Reconciliation of GAAP Loss from Operations to Adjusted Income (Loss) from Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Unaudited) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Three Months Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d31397dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF VIRACTA&#146;S BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta Therapeutics, Inc.
(&#147;Viracta&#148;) is a clinical-stage, precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. The association of viruses and cancer has been well characterized, and Viracta&#146;s lead
program is focused on cancers associated with the Epstein-Barr virus (&#147;EBV&#148;). EBV has been recognized as a Group 1 human carcinogen by the World Health Organization. Despite the association of EBV with cancer, attempts to develop vaccines
have not proven successful. EBV enters periods of latency during which most viral genes are epigenetically suppressed, which allows an infected cell to not be killed by the virus should it enter a lytic replication cycle. Likewise, the latently
infected cell can evade the body&#146;s immune surveillance mechanisms. In some stages of latency, no viral proteins are expressed on the cell surface, making it difficult to develop broadly effective immunotherapies. There are over 300,000 new
cases of <FONT STYLE="white-space:nowrap">EBV-associated</FONT> cancers each year with regard to lymphoma, nasopharyngeal carcinoma (&#147;NPC&#148;) and gastric carcinoma (&#147;GC&#148;), and there are currently no approved therapies for these
cancers, which are responsible for over 180,000 deaths each year. Viracta&#146;s novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which <FONT
STYLE="white-space:nowrap">in-turn</FONT> activate an antiviral drug. The activated antiviral drug disrupts the DNA replication cycle of the target cells resulting in chain termination and killing of the tumor cells by inducing apoptosis, also known
as programmed cell death. This synthetic lethality approach may also be applicable to other cancers associated with the herpes family of viruses, to which EBV belongs, such as glioblastoma associated with cytomegalovirus (&#147;CMV&#148;),
Kaposi&#146;s sarcoma with Kapois&#146;s sarcoma virus (&#147;KSV&#148;), and gastrointestinal carcinomas with Human Herpesvirus 6 (&#147;HHV6&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta&#146;s lead product candidate is an <FONT STYLE="white-space:nowrap">all-oral</FONT> combination of nanatinostat, Viracta&#146;s
proprietary investigational drug, and valganciclovir. Viracta has recently completed enrollment in the Phase 2 portion of its ongoing Phase 1b/2 clinical trial for the treatment of EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> lymphoma
and expects updated data from this trial in the second half of 2021. Viracta also plans to initiate its global pivotal trial in the second quarter of 2021. In addition, Viracta expects the clearance of a U.S. Investigational New Drug application for
the treatment of <FONT STYLE="white-space:nowrap">EBV-associated</FONT> solid tumors in <FONT STYLE="white-space:nowrap">mid-2021</FONT> and expects to initiate a global Phase 1b/2 clinical trial the second half of 2021. Viracta has received Fast
Track Designation by the U.S. Food and Drug Administration (the &#147;FDA&#148;) for the treatment of relapsed or refractory EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;lymphoid malignancies, in addition to orphan drug
designations for the treatment of post-transplant lymphoproliferative disorders (&#147;PTLD&#148;), plasmablastic lymphoma, <FONT STYLE="white-space:nowrap">and&nbsp;T-cell&nbsp;lymphomas.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Viracta team possesses deep, cross-functional experience and longstanding commitment to developing new medicines to benefit patients.
Collectively, the Viracta management team has extensive industry experience in both private and publicly-traded companies, <FONT STYLE="white-space:nowrap">having&nbsp;co-founded&nbsp;companies,</FONT> such as Hybritech, Inc. and IDEC Corporation,
raised substantial debt and equity capital, and discovered and developed oncology treatments at companies such as Novartis, Janssen and MorphoSys. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta&#146;s strategy is to
build a leading precision oncology company focused on virus-associated malignancies. While the association between viruses and cancer has been well characterized, there are currently no approved therapies that specifically target virus-harboring
cancer cells. Viracta&#146;s lead program targets an area of high unmet medical need with no approved therapies. Viracta&#146;s current pipeline is derived from its ability to leverage its synthetic lethality and biomarker-driven approach. Viracta
prioritizes virus-associated targets that it believes have the potential to change the paradigm of treatment in virus-associated cancers. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key elements of Viracta&#146;s strategy are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advance Viracta&#146;s lead product candidate,&nbsp;nanatinostat in combination with valganciclovir
,&nbsp;through clinical development, initially in EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;lymphomas; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand development of&nbsp;nanatinostat in combination with valganciclovir or variants thereof in other EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;malignancies, beginning with solid tumors harboring the EBV genome; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage its synthetic lethality approach and evaluate other malignancies associated with other viruses in the
herpes family; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate opportunities to combine&nbsp;nanatinostat in combination with valganciclovir or nanatinostat alone with
other therapeutic modalities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate other opportunities to expand Viracta&#146;s pipeline through licensing, acquisitions and/or
partnerships. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following figure summarizes Viracta&#146;s current development programs: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 1: Viracta&#146;s Development Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31397g0512204330773.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview of Virus-associated Malignancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The association of viruses and cancer has been well characterized. Despite knowing of EBV&#146;s association with cancer for over half a
century, attempts to develop vaccines have not proven successful. The figure below illustrates the association of a number of viruses with various cancers. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 2: Viral Infection and Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31397g0512204331054.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EBV, a member of the&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>-herpesvirus family, was the first
virus directly implicated in the development of a human tumor and is formally classified as a Group 1 human carcinogen by the WHO. Primary infection with EBV typically occurs in childhood, occurring first in the nasopharynx and is generally
asymptomatic; however, infection later in life may manifest as infectious mononucleosis. Once infected, individuals remain life-long carriers of the virus, with more than 90% of the world&#146;s population asymptomatically infected with EBV. The EBV
genome can be detected in approximately one out of one million circulating B lymphocytes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EBV Latency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EBV enters periods of latency during which most viral genes are epigenetically suppressed, as depicted in the figure below. In some stages, no
viral proteins are expressed on the cell surface, making it difficult to develop broadly effective immunotherapies. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 3: EBV
Latency in Cells </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31397g0512204331241.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Latent infection and intermittent reactivation are two important characteristics of the EBV
lifecycle. The maintenance of latent EBV infection requires the expression of a small subset of genes, and specific expression patterns (Types I &#150; III) of these genes are associated with
<FONT STYLE="white-space:nowrap">specific&nbsp;EBV-driven&nbsp;malignancies.</FONT> EBV has been shown to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">infect&nbsp;B-cells,&nbsp;T-cells,&nbsp;T/NK-cells&nbsp;and</FONT></FONT></FONT> epithelial cells, though its greatest predilection is <FONT
STYLE="white-space:nowrap">for&nbsp;B-cells.&nbsp;EBV</FONT> has been associated with a wide spectrum of human malignancies, <FONT STYLE="white-space:nowrap">with&nbsp;B-cell&nbsp;lymphomas</FONT> being the most common, and include EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;diffuse large B cell lymphoma, not otherwise specified (&#147;EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;DLBCL, NOS&#148;), Burkitt&#146;s lymphoma (&#147;BL&#148;), PTLD,
and lymphomas associated with congenital and acquired immunodeficiencies, <FONT STYLE="white-space:nowrap">including&nbsp;HIV-related&nbsp;lymphomas.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism of Action of&nbsp;Nanatinostat in Combination with Valganciclovir </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta&#146;s lead product candidate utilizes a combination of Viracta&#146;s oral proprietary epigenetic drug, nanatinostat, in combination
with the oral antiviral drug valganciclovir. Nanatinostat targets the EBV genome and induces the expression of certain viral kinase genes. Valganciclovir is converted to ganciclovir in the gut, and these viral genes then activate ganciclovir, which
disrupts the DNA replication cycle, leading to DNA chain termination and killing of the tumor cells by inducing apoptosis. This type of killing can be considered a form of synthetic lethality, where neither drug alone would be as effective in
killing the tumor cells, but together the two drugs are lethal to the tumor cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Epigenetic&nbsp;Re-Programming</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EBV gene products can drive aberrant cell proliferation, inhibit programmed cell death and other mechanisms that promote formation of cancer.
Viruses and cancers have also evolved mechanisms to evade immune detection <FONT STYLE="white-space:nowrap">by&nbsp;up-regulating&nbsp;immunosuppressive</FONT> signals, including the induction
<FONT STYLE="white-space:nowrap">of&nbsp;PD-L1.&nbsp;Due</FONT> to these pleiotropic <FONT STYLE="white-space:nowrap">effects,&nbsp;so-called&nbsp;molecularly</FONT> targeted approaches that target only one oncogenic activity have shown limited
ability to impact these cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Epigenetics refers to mechanisms that control which genes or gene programs are turned on or which ones
are silenced. Chemical modification of gene promoter regions via methylation, or acetylation or deacetylation of histones around which DNA is coiled, are major mechanisms by which gene expression is controlled. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">EBV-Associated&nbsp;Lymphomas</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">EBV-associated&nbsp;lymphomas</FONT> are a heterogeneous group of malignancies that harbor latent EBV within
the tumor cells. Within a specific histologic subtype of lymphoma, the frequency of EBV positivity may vary considerably. EBV is associated with approximately 5% of DLBCL in Western countries and
<FONT STYLE="white-space:nowrap">approximately&nbsp;10%-15%&nbsp;in</FONT> Asia and South America, whereas approximately 30% of peripheral T cell lymphoma (&#147;PTCL&#148;) and HL within North America are EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>, and endemic BL are EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;in approximately 95% of the cases. The risk for developing an
EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;lymphoma has been observed to be higher in the setting of immunodeficiency, including in patients with HIV, congenital immunodeficiencies and post-transplant <FONT
STYLE="white-space:nowrap">immunosuppression.&nbsp;EBV-related&nbsp;lymphomas</FONT> express a limited number of viral genes, with latency expression patterns associated with specific lymphoma subtypes. The limited expression of EBV genes may allow
for persistence of the viral DNA in cells by restricting the visibility of the virus to the immune system. The observation that lymphomas in patients with impaired immune function are more likely to express a greater number of viral genes is
supportive of this <FONT STYLE="white-space:nowrap">concept.&nbsp;EBV-related&nbsp;lymphoproliferative</FONT> disease in immunosuppressed patients may respond to therapies that improve immune function, such as reduced immunosuppression (e.g.,
transplant patients) or adoptive immunotherapy. In <FONT STYLE="white-space:nowrap">contrast,&nbsp;EBV-related&nbsp;lymphomas</FONT> that arise in immunocompetent patients generally express fewer viral genes and proteins, and as a result are less
prone to immune attack. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While outcomes vary based on the specific
<FONT STYLE="white-space:nowrap">malignancy,&nbsp;EBV-associated&nbsp;lymphomas</FONT> (e.g., DLBCL, HL, BL, and a number <FONT STYLE="white-space:nowrap">of&nbsp;T-cell&nbsp;lymphomas)</FONT> often present a treatment challenge as clinical outcomes
such as progression free survival and overall survival are worse following standard of care regimens as compared to those <FONT STYLE="white-space:nowrap">for&nbsp;EBV-negative&nbsp;patients.</FONT> The presence of EBV in lymphomas is therefore
generally considered to be a poor prognostic indicator. As shown in the figure below, across a series of patients with DLBCL, those who were EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;generally presented with more aggressive
disease, had lower response rates to first-line therapy, and poorer progression free survival and overall survival. In a meta-analysis evaluating survival outcomes across several lymphoma types (HL, DLBCL, T/NKCL, PTCL), EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;disease was associated with significantly worse overall survival. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 4: Outcomes <FONT STYLE="white-space:nowrap">in&nbsp;EBV-negative&nbsp;vs</FONT>
EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;Lymphomas </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g31397g0512204331397.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g31397g0512204331569.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Source: Lu TX, et al. Sci Rep 5,12168, 2015; Haverkos BM et al. Int J Cancer. 2017 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">EBV-positivity&nbsp;in</FONT> tumor cells can be detected using in situ hybridization <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">for&nbsp;EBV-encoded&nbsp;RNA&nbsp;(EBER-ISH).&nbsp;This</FONT></FONT> is a clinical laboratory test that detects the presence of EBV in the cancer cell. This test is currently most often
used to assist in the diagnosis of lymphoma subtypes. Because there has been a lack of actionable targeted therapies in <FONT STYLE="white-space:nowrap">past,&nbsp;EBER-ISH&nbsp;has</FONT> not been routinely used to guide course of treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Histopathological detection of EBV is included in the NCCN guidelines, which comment on the importance of determining EBV positivity utilizing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">either&nbsp;EBER-ISH&nbsp;and/or&nbsp;LMP-1&nbsp;immunohistochemistry</FONT></FONT> (&#147;IHC&#148;) in B and T cell lymphomas. Additionally, protocols established by the American
College of Pathology for both Hodgkin <FONT STYLE="white-space:nowrap">and&nbsp;non-Hodgkin&nbsp;lymphoma</FONT> include determination of EBV status. These laboratory developed tests are widely available in pathology labs, however the frequency at
which the testing is performed varies by treatment center and disease type and is lower in community treatment centers compared to academic institutions. This is likely primarily due to the absence of an available EBV targeted therapy, which impacts
the evaluation of treatment options for these patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several antiviral drugs have been tested in the clinic <FONT
STYLE="white-space:nowrap">against&nbsp;EBV-related&nbsp;lymphomas</FONT> but have not shown activity as single agent treatments. Antivirals that are prodrugs, such as ganciclovir, acyclovir and valganciclovir (an oral prodrug of ganciclovir) are
specific for the viral kinases and not the cellular kinases, and, therefore, require the presence of functional viral kinases, such as thymidine kinase (TK) and protein kinase (PK) for activation and are ineffective at
<FONT STYLE="white-space:nowrap">eliminating&nbsp;EBV-associated&nbsp;tumors</FONT> because these kinase enzymes are not being produced in the latent state. To overcome this barrier, Viracta utilizes its proprietary epigenetic drug candidate,
nanatinostat, to induce the expression of these viral kinase genes. Once induced, the viral kinases will phosphorylate and activate the the antiviral prodrug in the tumor cell, resulting in the killing of the tumor cell. Viracta has determined that <FONT
STYLE="white-space:nowrap">for&nbsp;EBV-associated&nbsp;malignancies,</FONT> oral valganciclovir, which is converted to ganciclovir in the gut, is its preferred antiviral drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nanatinostat belongs to a class of drugs known as histone deacetylase (&#147;HDAC&#148;) inhibitors. HDAC inhibitors have been explored in the
past, at high doses, as anti-tumor tumor agents. They were shown to have, in general, limited activity and in general, the efficacy they did exhibit was compromised by their adverse event profile. Nanatinostat is a highly potent class I HDAC
inhibitor, specifically targeting those few HDAC isozymes required for silencing of EBV in tumors. In contrast to the way in which other HDAC inhibitors have been tested in oncology, Viracta has used nanatinostat at low, epigenetically-active doses <FONT
STYLE="white-space:nowrap">to&nbsp;re-activate&nbsp;the</FONT> latent EBV gene expression, thereby lowering and in some instances, avoiding, certain issues common to all other HDAC inhibitors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>HDAC Enzymes and Inhibitors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, 18 HDAC enzymes have been identified in mammalian cells, varying in function, localization, and substrates. They are subdivided into
four main classes based on homology to yeast proteins. Three of the four classes (Classes I, II, and IV) are zinc (Zn2+) dependent enzymes and are inhibited by <FONT STYLE="white-space:nowrap">the&nbsp;pan-HDAC&nbsp;inhibitors.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Epigenetic modulation of gene expression is an essential biological process, with chromatin structure and gene transcription tightly regulated
by the acetylation state of histones in the nucleosome. Histone acetylation is a balance of the actions of histone acetyltransferases (&#147;HATs&#148;) and HDACs, with acetylation of histones generally associated with induction of gene
transcription and deacetylation with decreases in transcription. Though a seemingly simple concept, it belies the complexity of the effects of HDAC inhibition on chromatin structure. Exposure to HDAC inhibitors rapidly leads to compensating changes
in histone methylation and changes in expression of histone modulators. In tumor cells, the most commonly reported effects of HDAC inhibitors relate to induction of apoptosis, though they have also been shown to interfere with cell growth and
differentiation and inhibit angiogenesis. In addition, HDAC inhibitors have been shown to modulate immune responses which, in turn, affect many diverse cellular functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, more than 15 HDAC inhibitors have been tested in preclinical and clinical studies. HDAC inhibitors are broadly classified into four
main groups based on their structure: hydroxamic acids, cyclic peptides/depsipeptides, benzamides, and short-chain fatty acids. A common mechanism of action of these drugs is to bind a critical Zn2+ ion required for catalytic function of the HDAC
enzyme. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several HDAC inhibitors have demonstrated clinical antitumor activity when dosed at or near the maximum tolerated dose, with four
currently approved by the FDA for oncology indications. These are vorinostat for the treatment of cutaneous T cell lymphoma, romidepsin for the treatment of <FONT STYLE="white-space:nowrap">cutaneous&nbsp;T-cell&nbsp;lymphoma,</FONT> belinostat for
the treatment of <FONT STYLE="white-space:nowrap">peripheral&nbsp;T-cell&nbsp;lymphoma,</FONT> and panobinostat for the treatment of multiple myeloma. Common side effects seen with these HDAC inhibitors include thrombocytopenia, neutropenia, anemia,
fatigue and diarrhea. While HDAC inhibitors have displayed some antitumor activity as single agents, data suggest that the HDAC inhibitors may have a greater role as part of combination regimens. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rationale for the Combination of HDAC Inhibitors and Antivirals for the Treatment
<FONT STYLE="white-space:nowrap">of&nbsp;EBV-Associated&nbsp;Lymphomas</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Induction of the viral enzymes TK and PK within EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;lymphomas results in the sensitization of tumor cells to antiviral agents such as ganciclovir. This approach is also predicted to have high tumor specificity as
<FONT STYLE="white-space:nowrap">only&nbsp;EBV-containing&nbsp;replicating</FONT> cells would be targeted and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">neighboring&nbsp;EBV-negative&nbsp;non-replicating&nbsp;cells</FONT></FONT> would be unaffected. The potential for this approach was initially demonstrated in a patient who had
developed an EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;immunoblastic lymphoma in a donor lung four months after transplantation. Based on previous work that had shown that butyrate congeners could induce EBV lytic phase genes
(including viral TK13,14) a cell line derived from the patient&#146;s tumor was exposed to arginine butyrate, <FONT STYLE="white-space:nowrap">a&nbsp;pan-HDAC&nbsp;inhibitor,</FONT> which induced EBV TK transcription and in combination with
ganciclovir inhibited cell proliferation and resulted in cell death. Arginine butyrate was added to the patient&#146;s existing treatment with ganciclovir with no apparent additional toxicity. Though the patient succumbed to a systemic Aspergillus
infection that had preceded arginine butyrate therapy, subsequent pathologic examination of the tumor showed substantial necrosis compared <FONT STYLE="white-space:nowrap">to&nbsp;pre-therapy&nbsp;histology.</FONT> However, a definitive causal
relationship between arginine butyrate/ganciclovir therapy and antitumor effect was confounded by prior treatment with chemotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional clinical support was demonstrated in a Phase 1/2 investigator sponsored trial that combined the HDAC inhibitor arginine butyrate
with intravenous ganciclovir in 15 patients with recurrent EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;lymphomas. Arginine butyrate was administered as a continuous intravenous infusion daily on an escalating dose schedule within
each patient for 21 days of <FONT STYLE="white-space:nowrap">a&nbsp;28-day&nbsp;treatment</FONT> course, combined with a fixed daily dose of ganciclovir that was not interrupted. Eleven patients received at least one full cycle of therapy, and all
15 patients were evaluable for response. Antitumor activity was reported in 10 patients, with 4 complete responses and 6 partial responses. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Development Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Viracta&#146;s Combination Approach </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of&nbsp;nanatinostat in combination with valganciclovir is a novel therapeutic approach to target EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;malignancies, using <FONT STYLE="white-space:nowrap">a&nbsp;low-dose&nbsp;of</FONT> Viracta&#146;s oral proprietary epigenetic drug, nanatinostat, to target the EBV genome and induce the
expression of certain viral kinase genes. These viral genes then activate the antiviral prodrug, valganciclovir, which is converted to ganciclovir in the gut, and disrupts the DNA replication cycle. This disruption then leads to chain termination
and killing of the tumor cells by inducing apoptosis. This type of killing can be considered a form of synthetic lethality, where neither drug alone would be as effective in killing the tumor cells, but together the two drugs are lethal to the tumor
cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nanatinostat is a hydroxamic acid-based Class&nbsp;1 HDAC inhibitor and is a more than 2,000 times more potent inducer of the
latent EBV genes targeted by this approach than arginine butyrate, the first generation HDAC inhibitor previously investigated in an academic setting. Additionally, the class specificity of nanatinostat is critical for both the targeted efficacy and
safety of the approach. As a class, HDACs control the acetylation status of a range of histone <FONT STYLE="white-space:nowrap">and&nbsp;non-histone&nbsp;proteins,</FONT> giving these enzymes a key role in a number of vital cellular processes. HDAC
inhibition alters gene expression at many levels, including gene transcription, RNA expression, and signal transduction pathways. Cellular effects include control of the cell cycle, cell differentiation and senescence, inflammation, angiogenesis and
apoptosis. Nanatinostat has demonstrated pleiotropic activity both in vitro and in vivo across a range of human cancers in preclinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial clinical trial of nanatinostat was a single-agent Phase 1 clinical trial, wherein nanatinostat was administered as a single-agent
at oral doses ranging from 5 to 160 mg daily in 39 patients with refractory solid tumors. The maximum tolerated dose (&#147;MTD&#148;) for once daily continuous dosing of nanatinostat as a single agent was established as 80 mg, with a maximum
acceptable dose for once daily continuous dosing of 40 mg. This program was beneficial in establishing the initial safety profile and tolerability of nanatinostat before it was acquired by Viracta for the development of&nbsp;nanatinostat in
combination with valganciclovir. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nanatinostat induces the expression of EBV kinase genes to activate ganciclovir, rather than acting
directly as a cytotoxic agent. In clinical trials, nanatinostat has been active below the MTD and has been observed to <FONT STYLE="white-space:nowrap">be&nbsp;non-immunosuppressive.&nbsp;In</FONT> 46 patients with R/R EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;lymphomas in the ongoing Phase 1b/2 trial, the recommended Phase 2 dose regimen of nanatinostat 20 mg p.o. daily for four days/week, i.e., 4 days on, 3 days off, with valganciclovir 900 mg p.o.
daily has been generally well-tolerated with the most common grade 3/4 adverse events being reversible cytopenias. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nanatinostat in Combination with
Valganciclovir in Relapsed/Refractory EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;Lymphoma </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1b/2 Clinical Trial in
Relapsed/Refractory EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;Lymphomas </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, Viracta initiated a Phase 1b/2
dose escalation and expansion trial to evaluate the safety and preliminary efficacy and define a recommended Phase 2 dose (RP2D) of&nbsp;nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV+ lymphomas who had
received one or more prior therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trial is being conducted at approximately 20 centers in the US and 6 centers in Brazil. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 5: Design of Phase 1b/2 Trial in R/R EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;Lymphomas </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31397g0512204331803.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Twenty-five patients were enrolled in the Phase 1b portion of the trial, and the RP2D was determined to be
nanatinostat 20 mg p.o. daily for four days/week, i.e., 4 days on, 3 days off, with valganciclovir 900 mg p.o. daily. In December 2020, the initial results were presented from the Phase 2 portion of the trial, which showed that&nbsp;nanatinostat in
combination with valganciclovir demonstrated encouraging efficacy in multiple subtypes, including in HDAC inhibitor-refractory disease. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6: Summary of Efficacy per Subtype in Phase 1b/2 Trial in R/R
EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;Lymphomas, Presented at ASH 2020 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31397g0512204332006.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>* CR: complete response; PR: partial response; PD: progressive disease; ORR: objective response <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rate:&nbsp;B-NHL:&nbsp;B-cell&nbsp;non-Hodgkin&nbsp;lymphomas;</FONT></FONT></FONT> DLBCL: diffuse <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">large&nbsp;B-cell&nbsp;lymphoma;&nbsp;T-NHL:&nbsp;T-cell&nbsp;non-Hodgkin&nbsp;lymphomas;</FONT></FONT></FONT></FONT> ENKTL: extranodal NK/T cell lymphoma;
PTCL, NOS: <FONT STYLE="white-space:nowrap">peripheral&nbsp;T-cell&nbsp;lymphoma</FONT> not otherwise specified; AITL: <FONT STYLE="white-space:nowrap">angioimmunoblastic&nbsp;T-cell&nbsp;lymphoma;</FONT> CTCL: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">cutaneous&nbsp;T-cell&nbsp;lymphoma;&nbsp;IA-LPD:&nbsp;Immunodeficiency-associated</FONT></FONT> lymphoproliferative disorder; PTLD: post-transplant lymphoproliferative disorder; SLE: systemic lupus erythematosus; CVID:
common variable immunodeficiency disorder; PI: primary immunodeficiency; PBL: Plasmablastic lymphoma; HL: Hodgkins lymphoma. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 46 patients evaluable for safety, the RP2D was generally well-tolerated with the most
common grade 3/4 adverse events being reversible cytopenias. Serious adverse events (SAEs) occurred in 14 patients (30%); six in the Phase 2 cohort. SAEs occurring in&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2 patients were febrile
neutropenia and pneumonia (both n=2). No study drug related deaths occurred in the treatment period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 7: Grade 3/4
Treatment-emergent AEs in</B><B>&nbsp;</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B>2 Patients from the Phase 1b/2 Trial in R/R EBV</B><B><SUP STYLE="font-size:85%; vertical-align:top">+</SUP></B><B></B><B>&nbsp;Lymphomas Data Presented at
ASH 2020</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Overall (n=46)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase 2 (n=21)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>G3</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>G4</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>G3</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>G4</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thrombocytopenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">18&nbsp;(39%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">6&nbsp;(13%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">5&nbsp;(11%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">5&nbsp;(24%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1&nbsp;(5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2&nbsp;(10%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nausea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">17 (37%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">7 (33%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (10%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neutropenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">15 (33%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4 (9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9 (20%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">6 (29%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (10%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4 (19%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">14 (30%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9&nbsp;(20%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1&nbsp;(2%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">5&nbsp;(24%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4&nbsp;(19%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1&nbsp;(5%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lymphopenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10 (22%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4 (9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4 (9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4 (19%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (10%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leukopenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9 (20%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">3 (7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4 (19%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acute kidney injury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">6 (13%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Febrile neutropenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">5 (11%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4 (9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (2%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">3 (14%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (10%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hypokalemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">5 (11%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">3 (14%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Urinary&nbsp;tract&nbsp;infection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">5 (11%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (10%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">1 (5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hypertension</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">3 (7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2 (4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&#151;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pneumonia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 (7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (2%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (2%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 (10%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pivotal Trial of&nbsp;Nanatinostat in Combination with Valganciclovir in Relapsed/refractory EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;Lymphomas </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta plans to initiate
<FONT STYLE="white-space:nowrap">NAVAL-1</FONT> (Nanatinostat in Combination with Valganciclovir), a multinational, multicenter, open-label Phase 2 basket design trial. The trial will include multiple subtype-specific cohorts of R/R EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP> lymphoma patients designed to evaluate the anti-tumor activity of the combination treatment of nanatinostat with valganciclovir and is anticipated to enroll up to 140 patients. The primary endpoint
of the trial is objective tumor response rate as assessed by an independent review committee, while secondary endpoints include duration of response, survival outcomes, and the safety profile of the combined treatment. If successful, Viracta
believes this trial could support multiple U.S. New Drug Application filings across various EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> lymphoma subtypes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nanatinostat in Combination with Valganciclovir in EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;Solid Tumors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta intends to investigate&nbsp;nanatinostat in combination with valganciclovir in solid tumors. The annual incidence of NPC and GC is
estimated to be approximately 100,000 cases for each of the two malignancy types. Although some treatment options are available, there remains a high unmet need, particularly in patients with relapsed/refractory disease. Beyond NPC and GC, Viracta <FONT
STYLE="white-space:nowrap">believes&nbsp;EBV-associated&nbsp;breast</FONT> cancer, especially triple-negative, cervical, and other head&nbsp;&amp; neck cancers are potential areas for further investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">High tumor concentrations of nanatinostat have been demonstrated in murine xenograft mouse models of colorectal cancer. As shown in the figure
below, the combination of the class I HDAC inhibitor romidepsin with ganciclovir in human tumor murine xenograft mouse models of EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;NPC and GC has demonstrated a greater effect upon tumor
growth than the administration of either agent alone, providing the preclinical proof of concept for combining an HDAC inhibitor with an antiviral agent in solid tumors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 8: Murine Model of
EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;NPV and GC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31397g0512204332193.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Source: Hui KW, et al. Int J <FONT STYLE="white-space:nowrap">Cancer:138.125-136</FONT> (2016) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta expects the clearance of a U.S. Investigational New Drug application for the treatment of
<FONT STYLE="white-space:nowrap">EBV-associated</FONT> solid tumors in <FONT STYLE="white-space:nowrap">mid-2021</FONT> and expects to initiate a global Phase 1b/2 clinical trial the second half of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Preclinical Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Viracta also plans to explore the application of its synthetic lethality approach in other herpes family virus-associated malignancies, such as
glioblastomas associated with CMV. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g31397g0512204330773.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204330773.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #R I$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7)::C/%/&NU)2BM@=\@]: -5M;TY9!&;D;S"9P-I^X._3].M7HY%EC61#E'
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M48&2-P&,X[9S6?/X3@N;=();NX\M&D==AVG<YSG(ZX]*;)X265L-J,_E8<A
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M#V<?Z;.>_L/6O^AEF_\  9?\:/[#UK_H99O_  &7_&NAHH]K+R^Y?Y![./\
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M;_P&7_&NAHH]K+R^Y?Y![./]-G/?V'K7_0RS?^ R_P"-']AZU_T,LW_@,O\
MC70T4>UEY?<O\@]G'^FSGO[#UK_H99O_  &7_&C^P]:_Z&6;_P !E_QKH:*/
M:R\ON7^0>SC_ $V<]_8>M?\ 0RS?^ R_XT?V'K7_ $,LW_@,O^-=#11[67E]
MR_R#V<?Z;.>_L/6O^AEF_P# 9?\ &C^P]:_Z&6;_ ,!E_P :Z&BCVLO+[E_D
M'LX_TV<]_8>M?]#+-_X#+_C1_8>M?]#+-_X#+_C70T4>UEY?<O\ (/9Q_ILY
M[^P]:_Z&6;_P&7_&C^P]:_Z&6;_P&7_&NAHH]K+R^Y?Y![./]-G/?V'K7_0R
MS?\ @,O^-']AZU_T,LW_ (#+_C70T4>UEY?<O\@]G'^FSGO[#UK_ *&6;_P&
M7_&C^P]:_P"AEF_\!E_QKH:*/:R\ON7^0>SC_39SW]AZU_T,LW_@,O\ C1_8
M>M?]#+-_X#+_ (UT-%'M9>7W+_(/9Q_ILY[^P]:_Z&6;_P !E_QH_L/6O^AE
MF_\  9?\:Z&BCVLO+[E_D'LX_P!-G/?V'K7_ $,LW_@,O^-']AZU_P!#+-_X
M#+_C70T4>UEY?<O\@]G'^FSGO[#UK_H99O\ P&7_ !H_L/6O^AEF_P# 9?\
M&NAHH]K+R^Y?Y![./]-G/?V'K7_0RS?^ R_XT?V'K7_0RS?^ R_XUT-%'M9>
M7W+_ "#V<?Z;.>_L/6O^AEF_\!E_QH_L/6O^AEF_\!E_QKH:*/:R\ON7^0>S
MC_39SW]AZU_T,LW_ (#+_C1_8>M?]#+-_P" R_XUT-%'M9>7W+_(/9Q_ILY[
M^P]:_P"AEF_\!E_QH_L/6O\ H99O_ 9?\:Z&BCVLO+[E_D'LX_TV<]_8>M?]
M#+-_X#+_ (T?V'K7_0RS?^ R_P"-=#11[67E]R_R#V<?Z;.>_L/6O^AEF_\
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M_P#?;?XT9^O_ 'VW^-)10 N?K_WVW^-&?K_WVW^-)10 N?K_ -]M_C1GZ_\
M?;?XTE% "Y^O_?;?XT9^O_?;?XTE% "Y^O\ WVW^-&?K_P!]M_C244 +GZ_]
M]M_C3E.3W_[[;_&F4Y.M #\#_:_[Z/\ C1@?[7_?1_QHHH$&!_M?]]'_ !HP
M/]K_ +Z/^-%% !@?[7_?1_QHP/\ :_[Z/^-%% !@?[7_ 'T?\:,#_:_[Z/\
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M5;Y_X_IO^^!2?\(5;_\ /]-_WP*UYXGF_4ZW8XZBNQ_X0JW_ .?Z;_O@4?\
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M-CH3QG\JGAT@0ZD+Q;N4@((UB9%*JOH#C(SWH TJ*** "D;I2TC=* &4444
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M %%%% !1110 4444 %.3K3:<G6@!]%%% @HHHH **** "BBB@ HHHH ****
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M9/YT:!:7<IMXBMHW821LJ"'S0^X?.-N[Y?[WIP:%U[?*+=;"8W0)WP[T^50
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MPB.E>D__ ']_^M1[1!]1J^1P=%=Y_P (CI7I/_W]_P#K4?\ "(Z5Z3_]_?\
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MHI1UH ?1110 4444 %%%% !1110 4444 %%%% !1110 4C=*6D;I0 RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IR=:;3DZT /HHHH$%%%% !1110 4
M444 %%%% !1110 4444 %2Q_=J*I8_NT /HHHH&%%%% '/73L+J7#'[Y[^]0
M[W_O-^=%%,S#>_\ >;\Z-[_WF_.BB@ WO_>;\Z-[_P!YOSHHH -[_P!YOSHW
MO_>;\Z** #>_]YOSHWO_ 'F_.BB@ WO_ 'F_.C>_]YOSHHH -[_WF_.C>_\
M>;\Z** #>_\ >;\Z-[_WF_.BB@!_VB;_ )[2?]]&C[1/_P ]I/\ OHT44C0/
MM$__ #VD_P"^C1]HG_Y[2?\ ?1HHH /M$_\ SVD_[Z-'VB?_ )[2?]]&BB@
M^T3_ //:3_OHT?:)_P#GM)_WT:** #[1/_SVD_[Z-'VB?_GM)_WT:** #[1/
M_P ]I/\ OHT?:)_^>TG_ 'T:** #[1/_ ,]I/^^C1]HG_P">TG_?1HHH /M$
M_P#SVD_[Z-+]HG_Y[2?]]&BB@ ^TS_\ />3_ +[-'VF?_GO)_P!]FBB@ ^TS
M_P#/>3_OLT?:9_\ GO)_WV:** #[3/\ \]Y/^^S1]IG_ .>\G_?9HHH /M,_
M_/>3_OLT?:9_^>\G_?9HHH /M,__ #WD_P"^S1]IG_Y[R?\ ?9HHH /M,_\
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62%W9CQ]XY]:** -"BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g31397g0512204331054.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204331054.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %@ @D# 2(  A$! Q$!_\0
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M=R ,.Q//(J1VTZ6.'S#;.BG=%NVD CN/I7)GP#F*3_2HA.S?ZWRN2NS;M/\
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MU.1#GEOK7HR(L:*B*%51@ =JZ\+1DGSS-J4'?FD+1117<= 444A( R2 /4T
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M8*/QH ];75]/*@_;(.1_?%07'B/2+6:&*:^A4S':AW<$^E6DL+0(H-I!P/\
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M)&!_UKXQN/X"L3=32U"IP3ND-U9R5FQ&KT/X3P,;C4KC'RA53\<YKSO#.P1
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MMW4>EB&0V\C&3 V YZ]ZQY* *;C!S7JGAJ]-]H4$C'+J-C'Z5Y;)7H/@7/\
M8KYZ>8<4 =11110!R'B;PH;MVO;!0)3R\?\ >]Q[UPLB2V\ACE1D<=0PQ7M-
M5+S2[*_&+FVCD]R.1^- 'D'F4A?->E-X+T=F)$4@SV#FK5IX9TFS8-':JS#H
M7.[^= 'GMCHMU<Q_:YH9%LD(,C@<[>Y [XKU"PAMK>RBCM OD!1M*]QZU8"J
M%V@#;Z8KF+[5(_"5U%$ZN]C=RA8U"G]RQ(!YZ;><^U '444 Y&1WHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O9_P#'G%_NU/4%G_QYQ?[M
M3T %,E#M$XC;:Y4[6QG![4^B@#B1XMO7M825"26D!.I;%!*R[_+"C/3)#M]
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MBBB@ HHHH **** "BBB@"O9_\><7^[4]06?_ !YQ?[M3T %%%% !1110 $@
MDG '4FL.[\6Z/:2&,W!E8'!\I=V/QZ5S_C'799;IM+MG*Q)_KBI^\?[OTKED
MAXZ4 >E6?BS2+R01K<&)SP!*NW/X]*VP01D<@UXT\/'2NK\':[*ERNEW3EHW
M'[EF/*G^[]* .ZHHHH **** "F2_ZE_H:?3)?]2_T- "Q?ZF/_=%/ID7^IC_
M -T4^@ HHKC9?%U[!JMVAMTFMK:=HWCC@D#J@4'=YA.SOTH [*BN8;QG%&I>
M32[T+@J"H5B9 N[9@'.<$<]*JGQY&N^8V$C6PB1U9)%+%R2"N,]L4 =C17&Q
M^/X=_P"\TVZ*22 0^4N]F3:"6('3&<5?U3QC9Z5J*V<EO/(2F[<@& 2,@=>,
MX[T ='61X@T-=?M(;9[F2!$E61FCX8@=@>U9$GC?>$CM],G$XD19UE*XA#$8
M)P>>O:NNH 9%&(84C4L0HP"QR:?110 4444 %%%% !1110!BZOX9L=6S(R^5
M/_ST3O\ 7UKDKWP3?VJ/)%-%+&BEB<X.![5Z/6?K?VO^Q;O["BR7'EMM1NC<
M=* ."MO!VJ74<<@\I8W 8%F[5T.F>![6V=9;V3SV'.P#"_\ UZV]"%X-$M/M
MR)'<>6-R+T7VK1H :B+&@1%"J!@ #@4ZBB@ HHHH **** "BBB@ HHHH R?$
M.IW&E:?'/:Q)+*TZ1A';:#N..O:L23QZJ6<MRNF2,L9"D>:,L^TL5& <X ZU
MU5W9VU_;F"[@CGA8Y*2*&!_"JTFAZ5-;?9I-.MFAR#Y9B&.!@<?3B@#!M_&P
MFNT1+&22%V7=)O"^6&8*O'?DU:O_ !/)INNSV<]JIM4B5UE$F#G:[$$>F$K8
MCTG3HAB.RMU''2,#H<C\C27>D:=J#E[RQMYV*A29(PV0,X'/U/YT <ZGCHNZ
MG^R9?(8D^;YR_=#A"<?4CCO4D?C0RRP1)IDADN=KP*)E^:,ACN/H?D/'ZUT"
MZ78*H5;.  < !!QSG^8!ID.C:;;NSPV%O&S/O8K& 2V",_D3^= %;P_KJZ[9
MR3?9VMY(Y-CPNV60X!&1@8."*UZK6=A::?$T=G;10(S;BL:A03ZU9H ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"O9_\ 'G%_NU/4-H-MJB]U&#4U !15+5-2CTNR-P\;RL76..*/
M&Z1V(55&>.2>]9H\5VUJ\D.LQ'3;A-F$9O,$@?(785&2<J1C&?S% &_167'X
MDT:6>"&/486>>(2QX/!4@D'/09 /!]#40\6:$UJ;E=1B,8<)PK9)(R,+C)!
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@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g31397g0512204331241.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204331241.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #[ 98# 2(  A$! Q$!_\0
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M\]+O\I:KFFFG[-"]JRU]NM/^>MU^4M)]OM/^>MU^4M5*::?LT3[9EW^T+/\
MYZW7Y2TG]H6?_/:Z_*6J!IM/V2%[=]C1_M&S_P">UU^4M']HV7_/:Z_\BUFT
MAI^Q0U69I_VE9?\ /:Z_\BTG]I67_/>Z_P#(M99IM'L46JC-;^T['_GO<_\
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MC_R+7/T4>R06.OL94EE5XI)'C>/(W,Q[^AZ457T3_40?]<3_ .A45SL07/\
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MTDDVSW.[REP?FVC+<]N/6O-XKFSTRS>R$\J,^LW0G5]1>"-0&<H)9.64$8(
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M1)<?9XPGFR'EO\_RJ]10 4444 16_P#JV_ZZ/_Z$:EJ*W_U;?]='_P#0C4M
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MKJO%M_\ 8=#5S+/%YT\<6^&01$9/>0\(#T+=L\<UN%$.[*J=WWN.M*RJRE6
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M_P"NB?\ H0H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (K?\
MU;?]='_]"-2U%;_ZMO\ KH__ *$:EH **\\O9M2,6IWT>LWT4D6NI9Q(CC8D
M3/&A&T@@\.2,].,5)>ZC<:7-J.F-J6H21B_@B@;S5\W#Q;V3S7(" [3\QY'0
M=10!W,]W!:O L\JHT\@BB!_B?!.!^ /Y46MU!>VZW%M()(F) 8=#@D']0:\Z
MTS4KB_FLXI[AIEM?$@BB+SB9E3[.S8+@?-@D\_J:GTW4[B^6QAU/6;BRMOLD
M\ZSK,(S+(L[+@L>NU0#M[YYSB@#T2BO.-!GU'7%TV.?6K]4;1/M#-#)L:23S
M6 <G'IVJM=^([R[T:UE?4+M+I='BNG,=PELBR,#\Y)^:0DC[H4C\^ #U"F++
M&TKQ+(ID0 N@/*YZ9';.#7GIO-2U.TU&^.K7D#6^B6UW&ENX5?.:-V+$8Y&5
M''2M;PX%?Q?K%S)<2&>:TM)#$93M.Y"20OH#Q[9/K0!U]%%% !1110 4444
M+!_Q^?\ ;,_S%%$'_'Y_VS/\Q10!$G^MN/\ KJ?Y"I*F:T@9V8IRQR<,1FD^
MQP?W#_WT?\: (J*E^QP?W#_WT?\ &C['!_</_?1_QH BHJ7['!_</_?1_P :
M/L<']P_]]'_&@"*BI?L<']P_]]'_ !H^QP?W#_WT?\: (J*E^QP?W#_WT?\
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2S%%3QV\43;D7!(QG)-% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g31397g0512204331397.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204331397.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U 2D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#Q^VA\8>+/&WBRUL/&5QI=OIETL<,*V
MR2*0RYZG!'3WZUF7'Q \2OX-BCN+L0ZQI_B*/3+N>!0!.G.>,8&<=O2MS_A'
M_B%H7B_Q'J'A^WT62UU:Y64-=RMN4 8' ^I]:I7_ ,+-=B\#):6MS:WFO3:P
MNJW<DC%(BP!X'&<9(].IH ]-\4W4]EX2UB[MI#'/!9321N.JL$)!_.OGRV^(
M&M)I-A>67Q$FOM;E>,'1Y; !"S'!4R$8Q[UZGY/Q+U>QU#3=:LM!BM+JRGA#
M6TK[][(0O7C&2,UR+?#[Q_?>$;?PI<V'AF"R54C-X-S3J%.<YQUH Z35=6\3
M^*_'UWX6T+5ET2VTVV26[NEA$KO(P!"KGMS^AJ#Q'>^.?"OPP\03:IJD,MY:
MRQBQU"!0LCQF102ZXP#@_J?K5O4O!'B30_$B>(/!UW9RW$MG':7EMJ&0LVP
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MP6L1EN)HX8QU>1@H'XFF/?6D4<<DEU"B2D"-FD #D],'O0!RWQ5_Y)CKO_7
M?^A"N9\:V;Z7XCT3QE97BR76EV:FYTU2/,DM<XD=?INKIOBK_P DPUW_ *X#
M_P!"%5K]-%TSQEH>K:GJ BGO+ Z;!;/%E922K=>WI@^M '6:5J^GZW8I>Z;=
MPW5NW1XG# 'T..AYZ5>KS[4O!VK>'M2EUKP3.D9E=I+K29V(MIOEQE0!\K9
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M((/#FMZCX=E\1MJ-W*[7L=K)%AX$9LGYN^210!VU%%% !1110 4444 %%%%
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M]C<6RI&ML6:.10=TKD=4SR1[UZEID=]%IEO'J4\<]ZJ 32Q)M5F[D#L*MT4
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M*YOX@_\ ).O$?_8-G_\ 0#724 <UX*_Y!VI?]A>^_P#2AZZ6N:\%?\@[4_\
ML+WW_I0]=+0 4444 %><^//"^NW^N/J.BVUO<_;-*ETN9)9O+\H.<B3IR!Z5
MZ-10!Y=XQ^'4\W@$VUE>ZI/>VNGQ6T=I!<%89BF!DIW[_E6M!\-8/L\>[Q'X
ME5MHRHU$\''TJ[XXUS4].ET73-'DAAO=5N_(6XF3>(E"EB=O<\59\!>(KCQ1
MX2M=2NT1+DL\4PC&%+(Q4D>QQF@#-_X5I;?]#+XF_P#!D?\ "C_A6MM_T,OB
M;_P9'_"NWHH XC_A6MM_T,OB;_P9'_"C_A6MM_T,OB;_ ,&+?X5V]<KXZO\
M6M-TH76EWUAI]M$&DN[N[7>44#@*O0DG H YCP_X OKJ;5AJVM^)($BOGCLR
M-0(WP #:WOSFMK_A6EM_T,OB;_P9'_"N;UGXGZO9>$]'DBLHTUNYCBGO59?D
MMHF<*"03G+9&!Z9]*]:4Y4'U% '$_P#"M+;_ *&7Q-_X,C_A1_PK2V_Z&7Q-
M_P"#$_X5V]% '$?\*TMO^AE\3?\ @R/^%8NI> +^'Q+HUO9ZYXDDTV;S?MLO
M]H$F/"Y3GMDUZ3?7MOIMC/>W<JQ6\"&221CPJCDFO)A\3M>N=#\5:A';06IL
MIK<6<<RY=(I/XF&?F;!!V^^* .CM/A1IEA!Y%GKOB&"'<6V1WY49)R3@#N:G
M_P"%:6W_ $,OB;_P9'_"I_AUX@U#Q%H=U/J$D<LEO>26Z2K'Y32*N,,\?5&]
MC784 <1_PK2V_P"AE\3?^#(_X4?\*TMO^AE\3?\ @R/^%=O10!YSKGP[EMM"
MOYM-U_Q+-?) [6\9U G<X'RC&/6I-+^')FTFSEOO$/B6.[>!&G3^T2-KE1N'
M3US3=:U+QE:^/+#2[+4M->UO93(+?[,3)#;+C>S-G'7@>YHM?$/BB#XCV^C7
MLNGW$%UYLCVEJA+6<*_ZN1G]6/&"/I0!=_X5I;?]#+XF_P#!D?\ "C_A6EM_
MT,OB;_P8M_A7;T4 <1_PK2V_Z&7Q-_X,C_A1_P *TMO^AE\3?^#(_P"%=O7&
M?$7Q)?\ AVPTW[%-!9K>78@FO[B,O':J03N(_#'- &#I7@"^GU[6H;[7/$D5
MA#)&+&0:@1YBE,L<]\-6U_PK2V_Z&7Q-_P"#$_X5P]Q\6]7NM(TL6\]K9W+V
M\T]Q<_99)D?RY"@PJ\JIQN)/05[+IMU]MTNUNM\4GG1*^^$Y1LC.5)[4 <E_
MPK2V_P"AE\3?^#$_X4?\*TMO^AE\3?\ @Q/^%=O10!Q'_"M+;_H9?$W_ (,3
M_A6+KGP_OK:]T9-,USQ)-#->!+UCJ!/EP[22WMR!72?$37]7\.^%;F^T:R6>
M=(V9IG8!(% SN(_B/8#UK#\8^)/$^E:%8ZO8W6G06YM8W*2QEY;NX;&(E4=
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M3/%=3VAV[)[B-=JR,<9SW('!-=O110!S?Q!_Y)SXC_[!L_\ Z :Z2N;^(/\
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M\*P$3LV251FSC )/(&34UK\-+JWTW2K4ZC$S6.MMJC-Y9PRDD[.O7GK7H]%
M'F-G\,M2MI+>%]3MFL[37/[5A B;>022RL<XSTQ^-&H_#&\N;?5$2[T^;[9J
MKW_DW=L60JR@;20=RD>JD5Z=10!Y.?!.H:?8>%?#;7$UZ(]6_M"><*WEP1QC
M(1222!D@ $YZUZQ110 4444 %%%% !1110 4444 <W\0?^2<^(_^P;/_ .@&
MNDKFOB%_R3GQ'_V#I_\ T UTE '%V^F^(-(FO8=/UC3EMYKR:Y59].=V4R.7
M(+"90<$^@JQO\6_]!G2/_!5)_P#)%%% !O\ %O\ T&=(_P#!5)_\D4;_ !;_
M -!G2/\ P52?_)%%% !O\6_]!G2/_!5)_P#)%&_Q;_T&=(_\%4G_ ,D444 &
M_P 6_P#09TC_ ,%4G_R11O\ %O\ T&=(_P#!5)_\D444 &_Q;_T&=(_\%4G_
M ,D4;_%O_09TC_P52?\ R1110 F_Q;_T&=(_\%4G_P D4N_Q;_T&=(_\%4G_
M ,D444 )O\6_]!G2/_!5)_\ )%&_Q;_T&=(_\%4G_P D444 +O\ %O\ T&=(
M_P#!5)_\D4F_Q;_T&=(_\%4G_P D444 +O\ %O\ T&=(_P#!5)_\D4F_Q;_T
M&=(_\%4G_P D444 +O\ %O\ T&=(_P#!5)_\D4;_ !;_ -!G2/\ P52?_)%%
M% ";_%O_ $&=(_\ !5)_\D4N_P 6_P#09TC_ ,%4G_R1110 ;_%O_09TC_P5
M2?\ R11O\6_]!G2/_!5)_P#)%%% !O\ %O\ T&=(_P#!5)_\D4;_ !;_ -!G
M2/\ P52?_)%%% !O\6_]!G2/_!5)_P#)%)O\6_\ 09TC_P %4G_R1110 N_Q
M;_T&=(_\%4G_ ,D4;_%O_09TC_P52?\ R1110 ;_ !;_ -!G2/\ P52?_)%&
M_P 6_P#09TC_ ,%4G_R1110 ;_%O_09TC_P52?\ R11O\6_]!G2/_!5)_P#)
M%%% !O\ %O\ T&=(_P#!5)_\D4;_ !;_ -!G2/\ P52?_)%%% %'6-.\3:YH
=M[I5SK>EK!>0M#(T>EN&"L,'&9SS7=8HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g31397g0512204331569.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204331569.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U 1$# 2(  A$! Q$!_\0
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M_/#_ /X#3?\ Q==310!RWE>._P#G\\/_ /@--_\ %T>5X[_Y_/#_ /X#3?\
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MD5I(#;20EXUF1EY!&XD;3QG->L5S^CP7D?BKQ%+.LHMI&@^SEL[3B/#;?QH
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ME/<)X)F5_*WAC>1MCC^[U_"@#OJ*XS_A*/%G_0CS_P#@?%1_PE'BS_H1YO\
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M_!=+_P#$U%/\4=%A$96TU5MTBH<V$HP">OW?TH [>BN-_P"%F:'_ ,^VK?\
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M1R;3 D C8DY./EX^;GCCO6)X_N(KGX=W\\3AHY4B9#Z@R+0!UHZ"EI!T%+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 0WG_'E<?]<V_E7&^(O^2.2_]@V+^2UV5Y_QY7'_ %S;^5<;XB_Y
M(Y+_ -@V+^2T =Q1110!S/@O_CWUK_L,W?\ Z,-=-7,^"_\ CWUK_L,W?_HP
MUTU &')X=+2WDB7\J-.08_D4^5AMW'K\W/-8?Q TFS@^'EQYD2RO91QB*5QE
ME^=<GVZ5W%5-4LEU'2[FR=]BSQF,MC.,T 4AXJT#'_(9L?\ O^M'_"5>'_\
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MKP__ -!FQ_[_ "UJ"&$CB-#_ ,!%'D1?\\D_[Y% &7_PE7A__H,V/_?Y:/\
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M6LYE&L61)C8 ><OI6'X@97^#4C*0RG38L$?1:[7R82.(D_[Y%<Y\0@!\/]8
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M3_\ P4'_ ./444 ']F>+?^AFT_\ \%!_^/4?V9XM_P"AFT__ ,%!_P#CU%%
M!_9GBW_H9M/_ /!0?_CU']F>+?\ H9M/_P#!0?\ X]110 ?V9XM_Z&;3_P#P
M4'_X]1_9GBW_ *&;3_\ P4'_ ./444 ']F>+?^AFT_\ \%!_^/4?V9XM_P"A
MFT__ ,%!_P#CU%% !_9GBW_H9M/_ /!0?_CU']F>+?\ H9M/_P#!0?\ X]11
M0 ?V9XM_Z&;3_P#P4'_X]1_9GBW_ *&;3_\ P4'_ ./444 ']F>+?^AFT_\
M\%!_^/4?V9XM_P"AFT__ ,%!_P#CU%% !_9GBW_H9M/_ /!0?_CU']F>+?\
MH9M/_P#!0?\ X]110 ?V9XM_Z&;3_P#P4'_X]1_9GBW_ *&;3_\ P4'_ ./4
M44 ']F>+?^AFT_\ \%!_^/4?V9XM_P"AFT__ ,%!_P#CU%% !_9GBW_H9M/_
M /!0?_CU']F>+?\ H9M/_P#!0?\ X]110 ?V9XM_Z&;3_P#P4'_X]1_9GBW_
M *&;3_\ P4'_ ./444 ']F>+?^AFT_\ \%!_^/53U3PSXCUG39M.O?$MF;:<
8!9!'I95B,YX/FG'3THHH Z[%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g31397g0512204331803.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204331803.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #F E@# 2(  A$! Q$!_\0
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MG@;P_=77AO1Y[B;3;>2666QB9W8QJ2S$KDDGDDUM_P#"">$/^A4T/_P71?\
MQ-'@3_DGOAK_ +!5K_Z*6N@H Y__ (03PA_T*FA_^"Z+_P")H_X03PA_T*FA
M_P#@NB_^)KH** .?_P"$$\(?]"IH?_@NB_\ B:/^$$\(?]"IH?\ X+HO_B:Z
M"B@#G_\ A!/"'_0J:'_X+HO_ (FC_A!/"'_0J:'_ ."Z+_XFN@HH Y__ (03
MPA_T*FA_^"Z+_P")H_X03PA_T*FA_P#@NB_^)KH** .?_P"$$\(?]"IH?_@N
MB_\ B:/^$$\(?]"IH?\ X+HO_B:Z"B@#G_\ A!/"'_0J:'_X+HO_ (FC_A!/
M"'_0J:'_ ."Z+_XFN@HH Y__ (03PA_T*FA_^"Z+_P")H_X03PA_T*FA_P#@
MNB_^)KH** .?_P"$$\(?]"IH?_@NB_\ B:/^$$\(?]"IH?\ X+HO_B:Z"B@#
MG_\ A!/"'_0J:'_X+HO_ (FC_A!/"'_0J:'_ ."Z+_XFN@HH Y__ (03PA_T
M*FA_^"Z+_P")H_X03PA_T*FA_P#@NB_^)KH** .?_P"$$\(?]"IH?_@NB_\
MB:/^$$\(?]"IH?\ X+HO_B:Z"B@#G_\ A!/"'_0J:'_X+HO_ (FC_A!/"'_0
MJ:'_ ."Z+_XFN@HH Y__ (03PA_T*FA_^"Z+_P")H_X03PA_T*FA_P#@NB_^
M)KH** .?_P"$$\(?]"IH?_@NB_\ B:/^$$\(?]"IH?\ X+HO_B:Z"B@#G_\
MA!/"'_0J:'_X+HO_ (FC_A!/"'_0J:'_ ."Z+_XFN@HH Y__ (03PA_T*FA_
M^"Z+_P")H_X03PA_T*FA_P#@NB_^)KH** .?_P"$$\(?]"IH?_@NB_\ B:/^
M$$\(?]"IH?\ X+HO_B:Z"B@#G_\ A!/"'_0J:'_X+HO_ (FC_A!/"'_0J:'_
M ."Z+_XFN@HH Y__ (03PA_T*FA_^"Z+_P")H_X03PA_T*FA_P#@NB_^)KH*
M* .?_P"$$\(?]"IH?_@NB_\ B:/^$$\(?]"IH?\ X+HO_B:Z"B@#G_\ A!/"
M'_0J:'_X+HO_ (FC_A!/"'_0J:'_ ."Z+_XFN@HH Y__ (03PA_T*FA_^"Z+
M_P")H_X03PA_T*FA_P#@NB_^)KH** .?_P"$$\(?]"IH?_@NB_\ B:/^$$\(
M?]"IH?\ X+HO_B:Z"B@#G_\ A!/"'_0J:'_X+HO_ (FC_A!/"'_0J:'_ ."Z
M+_XFN@HH Y__ (03PA_T*FA_^"Z+_P")H_X03PA_T*FA_P#@NB_^)KH** .?
M_P"$$\(?]"IH?_@NB_\ B:/^$$\(?]"IH?\ X+HO_B:Z"B@#G_\ A!/"'_0J
M:'_X+HO_ (FC_A!/"'_0J:'_ ."Z+_XFN@HH Y__ (03PA_T*FA_^"Z+_P")
MH_X03PA_T*FA_P#@NB_^)KH** .?_P"$$\(?]"IH?_@NB_\ B:/^$$\(?]"I
MH?\ X+HO_B:Z"B@#G_\ A!/"'_0J:'_X+HO_ (FC_A!/"'_0J:'_ ."Z+_XF
MN@HH Y__ (03PA_T*FA_^"Z+_P")H_X03PA_T*FA_P#@NB_^)KH** .?_P"$
M$\(?]"IH?_@NB_\ B:/^$$\(?]"IH?\ X+HO_B:Z"B@#G_\ A!/"'_0J:'_X
M+HO_ (FC_A!/"'_0J:'_ ."Z+_XFN@HH Y__ (03PA_T*FA_^"Z+_P")H_X0
M3PA_T*FA_P#@NB_^)KH** .?_P"$$\(?]"IH?_@NB_\ B:/^$$\(?]"IH?\
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M4 ;M%<Q_PF D&^#3+B6)O,\M]RC=L^]U/'%1Q^*IMMW++;N+7>4AF4#Y3LW
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MV<YQT8?C4%IXK:6[D9[9S8O+&D<PP-FZ,-@C.3SF@#J**YP^+%6.-FT^<?:
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M$FW$ *WG-F, Y&WGC%;-% &0/#.F I^[E*JVXJ96*NV<Y89Y-6+/2+2QG:6
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M1YD?>)))"S?=*@9/8!CQ[UIT9% %2/3;6+3?[/2,BVV%-NXYP??K50>&]-V
M/')(WF&1G>0EG)78=Q[C;QCVK6HH QD\+Z;&A"K/ORI$OGL77:"!@YXX8CZ&
MDMO#T%MJEG<1A5@LH6CMTY+ L?F))//M]36UD44 9]]HMEJ,XFN$<MMV/M<J
M)%SG:P'45*NFVBV,EEY0-O)NW(3P=Q)/ZDU;HH R[?P]I]O+YHCDDEP09))"
MS$$8QD]L4RV\,Z9:SQ31QR&2$ 1EI6.T#H ,]!6O10!7ELK>:X\^2,,_EF+G
MIM."1C\*SU\+Z5'#!"D+K!#PL0E;81G(R,\X-;%% &,_A?2Y&<F.4;\A@)F
M()R1UZ9YQ6A96$&GQO';AE1VW%2Q(!]JLT9H @ELK>:UEMGB7R900Z@8SGK5
M671+&6R@M?+9$M_]2T;E63Z,.:T:* ,K_A'=.^S>4$EW;_,\[S6\S=Z[LYIQ
MT#3FTXV+0%X6?S&W.2S-G.2>I-:=% $%Q:075HUK,FZ%AC;G&,=,5GMX:TYH
MPK+,6YW2><VYP>H)SR/:M>B@#.70]/1%18-JKYFT!C@;_O5 OAC2U=F$4FUA
MRAE;;G;MSC.,XXS6Q10!F'0--:W:!H-T3.7*ECR2I7^1-0KX7TP'<4F9_E^=
MIF)X! '7IAB*V<CUHR* ,K_A'--$L;B)P$V_)YC;6*C"DC."0 .?859MM,M+
M22*2&,JT4 MU.XG"#D"KE&: *)TBS:\>[,1\YRQ9MQ_B55/Z*/RJO?Z'%=Z=
M96,3M##:RQ.NTG.U.@!Z@^]:U% &+)X5TJ1-K12@,FR3$S RC<6^8YY.YB?Q
MJ0^&]-)D/E/ER6!$C90E]^5]/FYK6HH RU\/Z>(98S&[B9!'(7D8EADMR<^I
M-,E\-Z=-O#K-L=V=T\YMK;CD@C.,$\_B:UZ* *U_86VI63VEW'OA?&5R1T.1
MTJK_ ,(_IF9?]&'[V1I7PQY9EVG]*TZ* ,Z'1+&!$58V.R5906<D[@  ?R J
M6XTJSNGG>:+>9XQ&_)Y4<CZ5<HH R#X;T]E ;[07!.9#.V]@>H)ST]J&\-:6
MTK2&%_FR=GF-M!(P2!G XK7HH H2:-8RQRH\1Q*$#$,0?E^Z0>Q%1IH-@B2*
M4D<RIL=GD9F89SR2?6M.B@"M9V$%B)1 &597WLI8D9]O2J,/ARR@W*DEUY3!
M@8C<,4PW7C/O6O10!F66@V-C)YB++(X3RU,TK/M7T&3P*LV&GVVF6HMK2/9$
M"6QDGD]>M6J* *MY9I=;)-JF:')B+YVAB,<CN*S['PS8VNGQVTB^8PB:-F!(
MR&.6X^M;5% &)>^&K6\OH;@/)$%SO\MRI;Y54<@\<+5I-#T^- B0;4$BR!0Q
MQN4;1^@K1HH R8O#>FQ.&$3G:5V!I&(C"G< N3P,]J?-H&G7$1BE@+(?,R-Q
M_P"6A#-^H!K3HH IV&F6VG&9H/,+3,&D:1RQ8@  \^P%7*** ,#QU_R3WQ+_
M -@JZ_\ 1344>.O^2>^)?^P5=?\ HIJ* $\"?\D]\-?]@JU_]%+4OBUVC\-W
M++(T?S1@LK%2 77/(Z<5%X$_Y)[X:_[!5K_Z*6MYT25"DB*ZGJK#(- '&/J'
M]G:E<)I-SOLF6%'>1VE2!V?&<D_W<\9]*%\47XO$1Y(&@CF\II(TR9?FQNQG
M(';(SR#78+;0)"85AC6(]4"#:?PH^RVX,9$$68_N?(/E^GI0!R^F^)-2N+TB
M2T\U&\S]S&5#Q[6VC^+GWR!39]>U)$GD,L4>ZZ,$,?DY("KN))+ 9_*NL6&)
M)&D2)%=_O,% )^II'MX9%*O#&RD[B&4$9]: .-LO$VJW5J+S$!C1XD:)4.7W
MD@X.>.GO33XAO9@$>>WFW1),4C5E:)C(!M//;/Z5VGD0A2HB0 ^BXJC9:'9V
M,\DR!Y)'&TF5MV!G./SH P/^$@U6&U6:0P-YT+.N(R!%B3;D\\C!SVK8T+49
MK^.]$TT,_D3F-98EP&& ?4\\UHW-E#=6[0.I56&,H=I'T-,T_3K?38&B@#8=
MB[,QR6)[T <79V>I26+7T>^%4,S/,;IF,HRP V=!5L:[J5E;1VLT\32M'"8Y
M!$?XEY!R<?B2*[((@3:%4+Z8XIKV\$B[7AC8<<,H/3I0!QEEXLU"9[>240F-
MQC9&NXLW/7G(SCT(]ZT_#FM7VIW#+<K%M,0D 4C*'.,8!/ZXK?%M KJX@C#J
M,*P09'TIT<,418QQ(A8Y8JH&3[T <MKC75OJ=ZRWDQ1M/=T3.%C(/;'?WJYH
M>IW,\=Q%))'="")'66-< DKG:>3S6\T:,<LBDXQR.U)'%'"NV*-$7.<*H H
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M&2Y)N$>=YY,DHJO@?0%NGO6//X=U@QQ11Q+^ZQY3B3E0)6;!)Z?*5QBN[HH
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MIQSP%GA\H( KA?+;=G=S_3TKIZ* .*?PM>_8415'G.)!.WFG+ NI'/T!HO\
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MF*27S-QE;=G=BJM[H&H3:M=R1PO^]NHYHY?/ C &W.Y.YX-=G10!Q-SX;O\
M^SUBC@1I)'F:5M^6W,?DZGIC\JBCT'4Y%D,]B%N! (8I5F&,X&YF[DG%=W10
M!G:)9RV.GF&8 /YTK\'/#.2/T-:-%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>.O^2>^)?^P5=?^BFH
MH\=?\D]\2_\ 8*NO_1344 )X$_Y)[X:_[!5K_P"BEKH*YWP0'/PZ\-!&"M_9
M5K@D9_Y9+6SY=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\
MY[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_
MWQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y
M=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_S
MW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_O
MB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S
M15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R
M[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\
MY[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_
MWQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y
M=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_S
MW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_O
MB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S
M15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R
M[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\
MY[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_
MWQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ1Y=W_SW3_OB@"S15;R[O\ Y[I_WQ2A
M+K/,R$?[M &1XZ_Y)[XE_P"P5=?^BFHH\=?\D]\2_P#8*NO_ $4U% ">!/\
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M<:E))KGW%*G6;B^38R_'_DMXRNY8;E+CS$C9F7H#L Q[],_C7,UW7_"J-?\
M^>]G_P!]G_"C_A5&O_\ />R_[[/^%:0KT8Q4>;8SGAZTI.7)N<+7MOP@_P"1
M6N/^OD_^@BN,_P"%4:__ ,][+_OL_P"%>E> /#UYX;T26TO7B:1YC(#&<C&
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MY&#1N7=MW+NQG&>: %HHHH *LQ?<_&JU68ON?C0!)567[]6JJR_?H 91110
M455OKF>V6(6UHUS-*^Q5#;57C.6/85BS>+HX[6.5;3YRDKR*\P4+Y3;6"MT8
MYZ"@#I**S-1U8V>G6MU#;&9[F6**.-FV'+],G!Q4<&NJD]Q;ZI"+":"-9CND
M#HZ$[<@X]>,8[B@#7HJG;:I8WC1K;W2.TC,JKR"2H!88/< @TP:UIAECC%[$
M6EP$QG!R2!ST&2"!GK0!?HHHH *LQ?ZL56JS%_JQ0!)5>;[WXU8JO-][\: *
MYAB:3S#&A<# 8CFD$$(&!$@'IMJ2BG=A8RY-2TZ&9T:,[U?;Q'U;V_.D;4=+
M!.8\L. /*Y8=\5873+2.269HP[N_F%FYQ]/RK-NY-&GBD2.1!(S ML'/\N*U
MBHO:YDW)=BP-7TI2D@7;SL5O+H&K:0H8A0/WFP_N^YJ"WN='<1P&':B_,KR+
MU/3^E*L^B2RS(8%&&W9*'YN,Y^E/E79BYGW1.NIZ=EMZ*""02$R!CIG\JD6_
MT^2-K@1DG<%.8_F)(R*@^T:"=CDP_-G;E3SFG)<:5<,EM#&L@E?:P Q@@<?I
M2<5V8[ONBS:3V5X7%O$"(R"6V8&3_6K/V: ?\L8^N?NCK2PV\-N&$,:H&.2%
M'6I*S;UT-$M-1JQHF=B*NXY.!UJW#]P56JS#]P5(R2BBB@ HHHH P/'7_)/?
M$O\ V"KK_P!%-11XZ_Y)[XE_[!5U_P"BFHH ;X&_Y)WX;_[!-K_Z*6M9_OM]
M:R? W_)._#?_ &";7_T4M:S_ 'V^M #:*** .:\0W$LMY_9PLKL6DL8^U7-O
M#O9US_JP>W?)K..GW/\ ;9=+:Z63[='+''M_T;R@ -S?[0&??(%=M10!@ZA,
M]EXIM[PVEU/!]D>/=!'OPQ92 ?RK!N;&^,1,FG2!+J::=4V&3RL@!05! #'&
M<GI7>44 <-!;ZBKZ982&53J$"?:0S?-'Y9Y_,<?E5S0K:ZM_$$F;:8Q-YF^6
M9"K+SP"<X<>G&174"U@6Z:Z$*"=EV&3'S$>F:EH **** %'WA]:MK]T54'WA
M]:MK]T4 !Z&JK_?;ZU:/0U5?[[?6@!M%%% '/^([JX22.S@L[DI/&1/=P0[V
M1.Z+[GGZ5BWFF3?;9/LUK>+EK?[+$J_N71-O^M]QSU]!BNZHH P]8DDMM<TJ
M\^RW$\4:3*_D1[RI8+CC\#6+=6UY+--=-ITJV][>&3RW0N8U6,*"R*>2Q![\
M5VU% ' 0V^J6^G:7;,9HY]11["9';#1J'+!\9[)O'XBM&RM;FV\6[DMIWC::
M3>\J$>6F."'!PZ\ !2,C/M74FV@:Z6Z,*&X5-BR$?,%],U+0 4444 %6X_N5
M4JW']R@!U5)/]8:MU4D_UAH ;1110!B^(+F_ACABL;2:0S$K)/"@9H5[X!(Y
M-8%]HTD@"P6%\L1M%BME1@"'W9/G<\@GGG(ZUW-% &%K*72'1K@6LEPUM,&F
M6W R/EP< D<9K*U"TU"\N+G4/[-=8YWBC\EP'<*N<N5!P>O3-=E10!P"VFH:
M;IT!56BNI;F2V2)R%)BDQ@@#CCD\5=&D7-EXBA:VM))(T= 7E *A0,%E?.1_
MN\UUS01/,DKQ(TD>=CE>5SZ&I* "BBB@ JS%]S\:K59B^Y^- $E59?OU:JK+
M]^@!E%%% &7KT&IW5DD&F/&A=\3EW*$Q]PI ."?6LFY\/74\=O\ Z#IY6.U>
MV%J[L8XB3PZG')QU^G6NJHH Q-0TJ]?1-.MK>5)KJSF@E+S$@2>7UR1ZU4O-
M'U>^>>]EEMHKLQQPQ11$[5C$F]_F(SN;H#CC%=-10!P]WH]]I]E.T;XU&YU!
M)K+87D*DH(V#,?\ 9W$DUH7/ANYBO(/[-:*".)(8Q,'8-M3J&3H^1TSC&:ZB
MB@ /7BBBB@ JS%_JQ5:K,7^K% $E5YOO?C5BJ\WWOQH BHHHH *SUT33D=G6
MV4,V<G)[G/\ .M"BFI-;":3W*7]DV6"/)R">02?K_6FC1K$;OW).X8.6/2K]
M%/GEW%RKL9QT+365 UL#L&%R3TSG^=20:396THDBBVL&W [CP<8J[11SR[AR
MQ[!1114E!5F'[@JM5F'[@H DHHHH **** ,#QU_R3WQ+_P!@JZ_]%-11XZ_Y
M)[XE_P"P5=?^BFHH ;X&Y^'?AL?]0FU_]%+6TT)+$YZGTK&\"?\ )/?#7_8*
MM?\ T4M=!0!7\D^OZ4ACQW_E_C5FFE : *C,B]6/Z?XU$;F!>K-^0_QJX;=#
MU%1FRC/:@"H;ZV'\3?D/\:/M]M_>;_OD?XU.=.B/\(I/[-B_NB@"(7MN?XF_
M(?XT];B%NC-^0_QJ0:?&/X14BVD8[4 -4*W0_P O\:<(L]ZE6%5[4\*!0!"(
M3GK^E3*,#%+10 'I4#1$L3S^53T4 5O)/O\ E2% .I_2K.*:8P: *I>)>LF/
MPJ,W-L.LP_*K+6JMVJ%M/C/84 1?;;0?\MQ^5'VVS_Y^!^5*=+C/:D_LJ/TH
M /MEH?\ EN/RIXN+=NDN?PI!ID8[5*MC&O84  V-T?/X4\19Z$_E3U@5>@J4
M*!0!!Y)]_P JF087!IW05R&O'Q1J :WL;,VUN>"WFKO<?GQ0!U<<\4V[RI4?
M:=K;6!P?0TUHBS9S^E>;:;X?\5Z5<^?:QE6_B'F+AOJ,UZ%IEQ>SV_\ I]G]
MGF7KAPRM[C!XH E\GW_2D,8'5OY58Q36C![4 56:)>L@J,W%N.LOZ59:U1NU
M1-81GL* (3>6HZS?I1]MM/\ GM^E..F1^@H_LR/TH 07=L>DWZ4]986Z2?I0
M-.C'85*MFB]J  *K='_E_C3O)]_TJ1857H*>!B@"'R#Z_I4J+M7%.HH *C:(
M,<U)10!%Y(]J:8\>GZU/1B@"D[%?X ?Q-0/<LO\ RP!_X$:TB@--,*GM0!DM
MJ#C_ )=O_'C3/[3?_GU_\>-:YMD/:D^RQ_W10!E#4G/_ "Z_^/&GK?.W_+M_
MX\:TOLL?I3A;H.U %-)F?K"!^)J=5W?P@?G4XC4=J=@4 1"$>U0WNH6FE6QF
MNYEC0=,]3]!4]P)S PMF192/E9QD#\*XO4/ ^I:I<-/=ZPLC'IF,X'T&: .O
ML-1M-3MQ/:3+(AZX/(^HJ=HPQYKB=.\$:EI=P)K36%C8=0(S@_49KM8!,(5%
MPR-*!\Q08!_"@!/)7T%(8@.P_(_XU-10!4<%>@'_ 'R?\:KO+,O1$_[Y/^-:
M6!2&-3VH QVNKD=(H_\ OD_XTS[9=_\ /*/_ +Y/^-;/DIZ4GD)Z4 9 N[H_
M\LH_^^3_ (U*MQ<'K&G_ 'R?\:T_)3TI1&H[4 4T:1OO*H_X"?\ &IUCSV'Y
M'_&IPH':EQ0!%Y*^@HDDBM86DED6.-1DLQP!4M8FK^&XM:DS=7MV(Q]V)&4*
M/PQ0!2C\=Z2^I&VRZQ=!.1\I/T]*Z9'21%>-@RL,AE.0:Y'_ (5UI/\ S\7?
M_?2_X5LZ1H*:+E;>]NGB/_+*1@5^O3B@#7HHHH P/'7_ "3WQ+_V"KK_ -%-
M11XZ_P"2>^)?^P5=?^BFHH 3P)_R3WPU_P!@JU_]%+705S_@3_DGOAK_ +!5
MK_Z*6N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH R?$&ISZ790R6Z*\DLZ189"^,]PH()/M69:Z]J]QJ4%I+9I
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MEB\N<Y,@+9)/U^F*V*** ,#QU_R3WQ+_ -@JZ_\ 1344>.O^2>^)?^P5=?\
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M_P 7110 ?\-(>&_^@/JOY1__ !='_#2'AO\ Z ^J_E'_ /%T44 '_#2'AO\
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M_P 7110 ?\-(>&_^@/JOY1__ !='_#2'AO\ Z ^J_E'_ /%T44 '_#2'AO\
MZ ^J_E'_ /%T?\-(>&_^@/JOY1__ !=%% !_PTAX;_Z ^J_E'_\ %T?\-(>&
M_P#H#ZK^4?\ \7110!2\0?'OPSK?A75M+BT[5H[F]LIK:,M''L#.A4$G?G&3
'Z4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g31397g0512204332006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204332006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $C 9 # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 <9I&LSV5]KD,>BZC=*-2D/F0*A7[J^K
MUJ?\))=?]"UK/_?$7_Q=<]JFMWGAOPCXLUFQ$+3VFH22!)D+*W"#'!'K5WPC
MXLO]9UW4].OEM@EM##+$ZHT+MO4$@QL2< GANAH U/\ A)+K_H6M9_[XB_\
MBZ/^$DNO^A:UG_OB+_XNL+7?&>J>'/$,L6H0VPT.;$,%^L;?Z/,1E1*-W*G/
M48J*[\8ZQ9^)[72G:V>*?2#?^9%8R2,'! QA7/R\YS0!T7_"277_ $+6L_\
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MXT =S17#?\)CXK_Z)_J'_@7#_C1_PF/BO_HG^H?^!</^- '<T5PW_"8^*_\
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MN-+>^L&MH-2^6"59 X#8R%;T- %O_A+-+]+W_P  I?\ XFC_ (2S2_2]_P#
M*7_XFK4^J%;^2RMH#//%$)74,!C/ '/<U0@\3L;6:>[L9+7[/<BWG#,&VDD
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M3*>-PK9_X2SP]_T&K'_O^M5_%=O"-(3$,8_TF+^$?WA6Y]F@_P">,?\ WP*
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M;9*<MYK[^,CMTKK/[1LO^?N#_OX*J_\ ".Z)_P! ?3__  &3_"C_ (1W1/\
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MN[BPELUM?(\IICDG=NR1T/T-;?\ PCNB?] ?3_\ P&3_  H_X1W1/^@/I_\
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ME1SP >_&*Q/^$?T(PF;[1/Y0."_VZ3&?3.ZD_L+P_AC]KE^0X;_3Y.#Z'YJ
M.DHKFWT+0(WV/=3*WH;^3/\ Z%3XO#FB3LRPS7$C+]X+?2''U^:@#H:*P_\
MA$]+_P"GS_P,E_\ BJ/^$3TO_I\_\#)?_BJ -RBL/_A$]+_Z?/\ P,E_^*H_
MX1/2_P#I\_\  R7_ .*H W**P_\ A$]+_P"GS_P,E_\ BJ/^$3TO_I\_\#)?
M_BJ -RBL/_A$]+_Z?/\ P,E_^*H_X1/2_P#I\_\  R7_ .*H W**P_\ A$]+
M_P"GS_P,E_\ BJ/^$3TO_I\_\#)?_BJ $\6?\@=/^OF+_P!"%;M<5XG\,:;%
MI2,GVK/VB(<W<A_B'^U6S_PB>E_]/G_@9+_\50!N45A_\(GI?_3Y_P"!DO\
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M/_8/$_\ T&[/_P  O_LJ/L'B?_H-V?\ X!?_ &5 '045S_V#Q/\ ]!NS_P#
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M>OX5NT <%_PD/Q#_ .A*M/\ P8K1_P )#\0_^A*M/_!BM=[10!P7_"0_$/\
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M_P#P%- &[7(ZWXJ;3/$-K&&'V".58+P[3PTGW6ST 4XS_O>U:/\ PE5M_P!
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MUL0/O"MK_A*K?_H'ZG_X"F@#=HK"_P"$JM_^@?J?_@*:/^$JM_\ H'ZG_P"
MIH W:*PO^$JM_P#H'ZG_ . IH_X2JW_Z!^I_^ IH W:YB.]O-6\3:E8+=M9P
MV 3:J ;I2PSN.>W:K7_"56__ $#]3_\  4U0NM1T:\NEN;C1=0>=1M$GV9@<
M>G!YH PM3U[5;#Q3/90W\SD7$"1!U'D@,,L&/;VKLM7OY8+K3+.)MK7DVUG'
M90,G%84C^'96N6D\/WS&Z \[-LQWXZ=^U3W.J:?/#:HFG:G&;5P\)%L3MQ^/
MI0!8$.K?V]+$FI^;:O"Q8%0/*?\ AQ_6M+0-2;5M$M[QUVNX(8>X./Z5SZ7&
MC6\TMS:Z1J4-U*"&E%NY//4X)Q5ZRUZQL+.*U@TW4UCC& /LIH Z6BL+_A*K
M?_H'ZG_X"FC_ (2JW_Z!^I_^ IH W:*PO^$JM_\ H'ZG_P" IH_X2JW_ .@?
MJ?\ X"F@#=KD/'G_ !ZVW_7.Y_\ 1+5I?\)5;_\ 0/U/_P !37->+=:BU%((
MDM;R(B&Y.9H2@_U+=Z -?X:_\DWT#_KS3^5=-<VT%U;O!<1K)"P^96'!KE/A
M])+#\+M$DAA,\BV2%8PP7=QZFK'BJ;49/#4,L<$L&9XS=QQMN=8<_. 1[>E
M&@^AZ&]G/;O;0-!.-DH9R=P]"<YQ[4/X:T.Y4DV43AHO(8AC\R?W3@\_C7+>
M+(M'/A.]FTY7WXA"A ^,^8/UQG/M5OP'(\4^JVMUNAN6G\U;8!O+1-H *$]0
M>OU- '36^AZ9:W45S!:(DT4?E(X)SM].O/XTDFC:4]S)=26L1E8DNQ/<C!..
MF<<9JQ?S3P6$TMM"9IU7Y(QW-<5X7>]N)-3LKF"Y4R:HSLT_]Q0I./QP/QH
M[*XTVQN[BWN)X5>6U.Z)MQ'EG'^%);Z9I\%V]Y;V\:S29S(O?)R?S/6N/O9I
MGM_$L=JTI5-1@,@4'(AQ'YFW\ _3WK9\(^9Y>IE XL#>-]C#9^Y@9QGMNW4
M:]_8Q7IMR6"3V\HFA;N" 0?P()'XU&-(TJ.:6X^S0AY=P=B>"6^]QTY[UCF[
MOAJ^OM% \T\#0Q6Z#LC("6'XEORKDK-[@VT:ZG#>+8I<:F"),EC)YF8^GMN
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M\)AH7_/]_P"0G_PH W**P_\ A,-"_P"?[_R$_P#A1_PF&A?\_P!_Y"?_  H
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M3L_^_P O^- %[RH_^>:?]\BCRH_^>:?]\BJ/]O:1_P!!.S_[_+_C1_;VD?\
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M#7^MUO\ ["<O_H*5O4 5/[*T_P#Y\;;_ +]"L#^V_#(OY;-[1(Y([C[,2]N
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MZ#\*62QO;#QA<:LMJUY;75LD.$(WQ%23T/8Y_2@"O!I_A"YOELH51[AHS*J
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M\_EO_P!_5_QH LUD7&OPP6&J7RQ-+;Z<'WE3R[(,L!].GUS5[^T++_G\M_\
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M^T++_G\M_P#OZO\ C0!8"@#  'X4M5O[0LO^?RW_ ._J_P"-']H67_/Y;_\
M?U?\: +-%5O[0LO^?RW_ ._J_P"-']H67_/Y;_\ ?U?\: +-%5O[0LO^?RW_
M ._J_P"-']H67_/Y;_\ ?U?\: ,OQ9_R!T_Z^8O_ $(5NUS?BJ^LVTA MU 3
M]HBZ2#^\*V_[0LO^?RW_ ._J_P"- %FBJW]H67_/Y;_]_5_QH_M"R_Y_+?\
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M_P"PG+_Z"E;U<=H_B#3-.O=<@NIV20:E(<")V_A3N!6M_P )=HG_ #]O_P"
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M^$NT3_G[?_P'D_\ B: -NBL3_A+M$_Y^W_\  >3_ .)H_P"$NT3_ )^W_P#
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M+_PB'AK_ * &F?\ @*G^%'_"(>&O^@!IG_@*G^%;5% &+_PB'AK_ * &F?\
M@*G^%'_"(>&O^@!IG_@*G^%;5% &+_PB'AK_ * &F?\ @*G^%'_"(>&O^@!I
MG_@*G^%;5% '&>)_"OA^'2D:+0].1OM$0RML@.-P]JV?^$0\-?\ 0 TS_P !
M4_PIGBS_ ) Z?]?,7_H0K=H Q?\ A$/#7_0 TS_P%3_"C_A$/#7_ $ -,_\
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M:E_X,[G_ ..444 '_".6/_/;4O\ P9W/_P <H_X1RQ_Y[:E_X,[G_P".444
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%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g31397g0512204332193.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204332193.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% 2T# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W5I'WMAR
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M]7_"MS$B;_6-]324K?ZQOJ:2@ HHK,O-1EM-8M('$(M)HI'>1B=RE,'Z8P:
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MN^GUK3L+R/4+&&[B5U25=P#KAA]14'V&]_Z"T_\ WZC_ /B:/L5[_P!!:?\
M[]1__$T"U+]%4/L-[_T%I_\ OU'_ /$TP+=VM]:I)>O.DK,K*\:#&%)[ >E
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M375O9R36L<+M&I9A*Y48 SQ@&C3IKNXM5ENXX49P"HB<L,>^0*=J'_(,N_\
MKB_\C2V'_(/M_P#KF/Y4 6**** "LG3?^/:3/_/5_P"=:U9.F_\ 'O)_UU?^
M=8U/CC\_T-J?P/Y?J5=:A;9#)'<W$),JH1'(5&#[5IQ1B&)8P[OM&-SMDG\:
MHZS_ ,>\'_7PE:-,04444##%%%% !3))4AC:21@J*,DGM3Z* *MIJ5E?,RVM
MS'*R?>"'.*M5G:3_ ,OO_7T_\A6C0 4444 %%%% !2%E!P6'YTM8FH:;83:[
M8O+96SLY<LS1*2V%[\<T ;=%     P!T HH **** "J>J_\ (+N?^N9JY5/5
M?^07<_\ 7,UG5_AR]"Z?QKU-1/\ 5K]!5BWZO^%5T_U:_058M^K_ (5T+8YG
MN1-_K&^IK.US55T31KG47C\P0@';N"@DD 9)Z#GDUHM_K&^IK)\2F\7PY>FP
MA\ZY\O"Q^6'R,C=A3PQQG -,#.\*^+3XFFNA]B\B) )('$N_S(RS*"1CY2=A
M..>"*Z%KJW2Z2V:>,7#J66(L-Q ZD#KBN3\#_P!N;[I]6A$,<L:21Q>0D?DY
M+8C&T<A5V=<X.:W=0TV2[U*TN$*HL<4T;O\ Q#< !C\C0!-_;6E?9Y9_[1M?
M)B;9(_G+A6]"?6I;MUDTNX=&#*T+$,#D$8KDH/#NJPW5C>FWMM]E''"+=9?E
ME"HZELXX^_P#V%:L>D7MCX8AM!J#1&WM/+<)&K!B%[;AF@#7TW_D&6O_ %R7
M^55[;_D/7W_7./\ K6'XBU2]TKPMITMC/Y,LCHA?8K<;">A!'85QR>)->2YD
MG75'\R0 ,?)BYQT_AH ]6U#_ )!EW_UQ?^1I;#_D'V__ %S'\JY&V\:V<OAM
M(KV6:2_DM!YA2W8@LR9[#'>M/2/%6EW)M+%'F$[J$4/ R@D#.,D8[5/-&]KB
MYEL='1115#"LG3?^/>3_ *ZO_.M:LC3SBUE(_P">K_SK&I\<?G^AM3^!_+]2
M/6?^/>#_ *^$K1KR>?Q%K=V,2:DP59-P ACX(/'\-=-X1UO4M0O[F*_N_.C2
M(.,QJN.?]D"J<78E25SLJ*HPZUIEQ/Y$-_;R2DX"+("<_2KU(H**** "BBN/
M\8ZSJ6FWMI#8W1@62-F;$:MD@_[0-"5P;L;^D_\ +[_U]/\ R%+J.I2V#1XL
MI)DD=4#*ZCYB<#J:\ZM/$.M6\XVZBS+),'=3#'R3@'^&O0M:_P!3:?\ 7W%_
MZ%3:L2G<T(F=XE9XS&Q'*$@X_*GT44B@HHHH *S;O_D-:=_VT_\ 033];N9;
M/0[ZY@;;-%"S(V <$#WKS9_$&MRSPSMJ;^9%G:?)CXR,'^&FE<ENQZK-(8H6
MD$;R%1G8@R3]*IZ?JJZBSA+6ZB5"5+2H ,@X(ZUE^#M3O=3TZX>^G\Z2.;8K
M;%7C /8 =ZT=%_X][C_KZE_]"I#O<TJ***!A5/5?^07<_P#7,U<JGJO_ ""[
MG_KF:SJ_PY>A=/XUZFHG^K7Z"K%OU?\ "JZ?ZM?H*L6_5_PKH6QS/<B;_6-]
M37'_ !"UK3=/T(Z??7,L$FH I"8XG?<002IV<@$<<>M=@W^L;ZFN4\;Z=XCU
M2SM[?0#IP4D_:/MB!LCC&W<C#UZBF!A_#/3X;.^U9[6&6*U;:(C+;31LZ[F(
M),@ZX(&!QQGO7HU<7X"\,7_AP7@O;6WA\W:08;QY0QYS\I557_@(KM"< GTH
M *KWW_(/N?\ KDW\C7.6/C5=1"I:V(DN)) D<8G&,E2Q#G'RL O(P>HK8748
M=1\._;8_D2>V+JKG!&5Z4 <SXR_Y%+2O^NR?^@-7#5W/C+_D4M*_Z[)_Z U<
M-0(?9?ZE/^N47_HM:V=!_P"1FTO_ *['_P! :L:R_P!2G_7*+_T6M;.@_P#(
MS:7_ -=C_P"@-7E_\Q/S.1_Q?F>K4445ZAV!6/8?\>DO_71_YUL5CV'_ !Z2
M_P#71_YUC4^./S_0VI_ _E^IY&O0_P"\?YUU7@3_ )#%U_UP'_H1KE5Z'_>/
M\ZZGP*0-8NB2!^X'7_>-:O8RCN=A9_\ (9U+_MG_ .@UHUF6;K_;.I?,O_+/
MO_LUI_2LS1!1110,*X'Q]_R%+'_KBW\Q7?5P/C[_ )"EC_UQ;^8IQW)EL<KN
MV,C8SM8''XUU%[XOO+U8@NF0*L<RR FZ/.T]/N5RK]/Q%7$^[^)_G6&*J2@E
MRG-5J2@M#O\ P_XBFUFXGAFLTMS&H8%)B^?_ !T5OUQ'@G_D)7?_ %R'\Z[>
MJI2<H)LWI2<H)L****T-#*\2_P#(LZE_U[O_ "KRL=!7JGB7_D6=2_Z]W_E7
ME8Z"KB9S'P;B53>X7=(<*Q SB/TJ5D$,;-&TB$9;Y7(Y]>M16_\ K$_WI?\
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M_P#(N6'_ %R%><'H?I7H_AK_ )%RP_ZY"N+"-NYGA&[LU:***[3M"N!\??\
M(4L?^N+?S%=]7 ^/O^0I8_\ 7%OYBG'<F6QR;]/Q%7$^[^)_G5-^GXBKB?=_
M$_SKEQNR./$;(Z?P3_R$KO\ ZY#^==O7$>"?^0E=_P#7(?SKMZNA_#1T4/X:
M"BBBMC8RO$O_ "+.I?\ 7N_\J\K'05ZIXE_Y%G4O^O=_Y5Y6.@JXF<Q]O_K$
M_P!Z7_VG4\W^I?Z5!;_ZQ/\ >E_]IU/-_J7^E>97_C?<<-7^(>NI]Q?I3J:G
MW%^E.KT#T@JGJO\ R"[G_KF:N53U7_D%W/\ US-9U?X<O0NG\:]343_5K]!5
MBWZO^%5T_P!6OT%6+?J_X5T+8YGN1-_K&^IKGO'$:S>#-3C>6&)6C 9IF8)C
M<.&*@G!Z<>M="W^L;ZFN.\;>(;O2;G3=/MA<JM^)0TUG!YT\94 @HIX/OD'B
MF!E_#-]/:?4!91:1&P5-_P#9\L[GOC=YH&/PKT&:3RH))-I;8I;:.IP.E<AX
M))FN[ZYGGUVXNG1%:74[1;<;1G 4* #U.:[*@#A+7Q)J-T;2VGN_LTMXR2-/
M'Y;)#&R.P5<C@Y3'S9_6MF+6I9_"T%Q<VMP\UQ9[W,,)*@E?TK9_L^R\J2+[
M';^7(VYT\I<,?4C')I;T!=-N   !$V /H: ..\8_\BCI7_7:/_T!JX:NY\9?
M\BEI7_79/_0&KAJ!#[+_ %*?]<HO_1:U<M[\:5J%I?M&9%@=G* X)PC53LO]
M2G_7*+_T6M-U'_CV_P" O_Z U>8O]Y^9QO\ BFTWQ5A;5([S^R)-JQ&/;YXS
MR<^E>@>&M=3Q'HL>HI;M '=EV,V[&TXZU\Z#H*]#\,_$+3/"?ABSL[VVNY9)
M&ED!A52,;R.Y%?18G#1A%. L-B)U)-2/3/#W_(#M?]W^M16'_'I+_P!='_G7
M$^&_BKHSBQTK['?":1A&&*IMR3_O5VUA_P >DO\ UT?^=>7534XW\_T/4I/W
M)?+]3R->A_WC_.E3_CZ'_ ?YFD7H?]X_SI4_X^A_P'^9HK?PV<T_A9=/0_2O
M1_#7_(N6'_7(5YP>A^E>C^&O^1<L/^N0KBPG4SPF[-6BBBNT[0K@?'W_ "%+
M'_KBW\Q7?5P/C[_D*6/_ %Q;^8IQW)EL<F_3\15Q/N_B?YU3?I^(JXGW?Q/\
MZY<;LCCQ&R.G\$_\A*[_ .N0_G7;UYKHNNV.@SW,]](\:2($4HA8Y^E6+3X@
MZ<E_(;C5[N2V7&Q39@;NN<X&?2ML-3G*DFD:T:D(P2;/0J*AM;F*\M(KF$DQ
M2J'0D8X-359TF5XE_P"19U+_ *]W_E7E8Z"O5/$O_(LZE_U[O_*O*QT%7$SF
M/M_]8G^]+_[3J>;_ %+_ $J"W_UB?[TO_M.IIO\ 42'_ &37F5_XWW'#5_B'
MI^H:A-I\43I:&9&9$R) N"Q"CK[FKT+2/$K2Q^6YZKNSC\:\[U7XD:9-%]E2
MRO-T5PA)(3!V."?XO:ND\.>,K'Q+<S06MO<1-$F\F4+@C..Q->HZ-2,>9K0[
M8UJ<I<J>IT=4]5_Y!=S_ -<S5RJ>J_\ (+N?^N9KGJ_PY>AT4_C7J:B?ZM?H
M*L6_5_PJNG^K7Z"K%OU?\*Z%L<SW(F_UC?4U6EM+6:\M[B6*-KF -Y+D?,F1
MAL?6K+?ZQOJ:Y+QS!J<]M:?V9I27LBLQ\SGS(C@8VD2(5SW()QCH:8&OIOB/
M2]7NYK6RN&DEB!8@QLH8 X)4D889XR*U:Y[P]X<.B7,TH-NXG7+L8%68-U(+
MK@,.O8'ZUOOO\MO+"E\';N/&>V: %) &21Q4%]_R#KG_ *Y-_(UPZ:/K$-[-
M)J=C]LMFNUFN%AD,GG_NB,A2!P&QQV_#-;L%OK%KX5MX#]G,D=GMF\YF+!MO
MJ.M &3XR_P"12TK_ *[)_P"@-7#5W/C'_D4=*_Z[1_\ HMJX:@0^R_U*?]<H
MO_1:TW4?^/;_ ("__H#4ZR_U*?\ 7*+_ -%K3=1_X]O^ O\ ^@-7F+_>OF<<
MOXAQPZ"HM;_X\M,_ZYR?^C&J4=!46M_\>6F?]<Y/_1C5]9B=HG/@_B8SPQ_R
M-6E_]?*?SKZ2L/\ CTE_ZZ/_ #KYM\,?\C5I?_7RG\Z^DK#_ (])?^NC_P Z
M\?%_Q8^C/8H?!+Y'D:]#_O'^=*G_ !]#_@/\S2+T/^\?YTJ?\?0_X#_,UC6_
MALQG\++IZ'Z5Z/X:_P"1<L/^N0KS@]#]*]'\-?\ (N6'_7(5Q83J9X3=FK11
M17:=H5P/C[_D*6/_ %Q;^8KOJX'Q]_R%+'_KBW\Q3CN3+8Y-^GXBKB?=_$_S
MJF_3\15Q/N_B?YURXW9''B-D9.O_ /'J/]\?R-<V>E=)K_\ QZ#_ 'Q_(USA
MZ5[N4_[JCSL1\2]#Z#\.?\BWIO\ U[I_*M2LOPY_R+>F_P#7NG\JU*\Q[GO1
MV1E>)?\ D6=2_P"O=_Y5Y6.@KU3Q+_R+.I?]>[_RKRL=!51(F/M_]8G^]+_[
M3J:?_CWD_P!TU#;_ .L3_>E_]IU-/_Q[R?[IKS*_\?[CAJ_Q#CKO_C^N?^NS
M_P#H1KN?A1_R&;__ *]Q_P"A"N&N_P#C^N?^NS_^A&NY^%'_ "&;_P#Z]Q_Z
M$*^KQ/\ NWW'-AO]Y^\]8JGJO_(+N?\ KF:N53U7_D%W/_7,UX%7^'+T/>I_
M&O4U$_U:_058M^K_ (573_5K]!5BWZO^%="V.9[D3?ZQOJ:2E;_6-]324P"B
MBB@ JO??\@^Y_P"N3?R-43XDTY0X9IUD5PGDM;N)&)!(PN,D8!/'H:M2W$-W
MHLMS;R"2&6!G1QT(*\&@#DO&7_(I:5_UV3_T!JX:NY\9?\BEI7_79/\ T!JX
M:@0^R_U*?]<HO_1:TW4?^/;_ ("__H#4ZR_U*?\ 7*+_ -%K3=1_X]O^ O\
M^@-7F+_>OF<<OXAQPZ"HM;_X\M,_ZYR?^C&J4=!46M_\>6F?]<Y/_1C5]9B=
MHG/@_B8SPQ_R-6E_]?*?SKZ2L/\ CTE_ZZ/_ #KYM\,?\C5I?_7RG\Z^DK#_
M (])?^NC_P Z\?%_Q8^C/8H?!+Y'D:]#_O'^=*G_ !]#_@/\S2+T/^\?YTJ?
M\?0_X#_,UC6_ALQG\++IZ'Z5W%E%O\%6[B26-H[<LIBD9#GGT/-<.>A^E85]
MXAUB!C9PZE/';! HC4X&*Y\NHRJS<8G-2JQI)RD>VZ;"(K&(^9*Y=%9C)(SG
M./<U<KR#P1XAUBZ\3V=I<:C/+;E2#&YR.!Q7K]=M:E*E+ED=M&K&K'FB%<#X
M^_Y"EC_UQ;^8KOJX'Q]_R%+'_KBW\Q6<=RY;')OT_$5<3[OXG^=4WZ?B*N)]
MW\3_ #KEQNR./$;(R=?_ ./0?[X_D:YP]*Z/7_\ CT'^^/Y&N</2O=RG_=4>
M=B/B7H?0?AS_ )%O3?\ KW3^5:E9?AS_ )%O3?\ KW3^5:E>8]SWH[(RO$O_
M "+.I?\ 7N_\J\K'05ZIXE_Y%G4O^O=_Y5Y6.@JHD3'V_P#K$_WI?_:=33_\
M>\G^Z:AM_P#6)_O2_P#M.II_^/>3_=->97_C_<<-7^(<==_\?US_ -=G_P#0
MC7<_"C_D,W__ %[C_P!"%<-=_P#']<_]=G_]"-=S\*/^0S?_ /7N/_0A7U>)
M_P!V^XYL-_O/WGK%4]5_Y!=S_P!<S5RJ>J_\@NY_ZYFO J_PY>A[U/XUZFHG
M^K7Z"K%OU?\ "JZ?ZM?H*L6_5_PKH6QS/<B;_6-]324K?ZQOJ:2F 4AS@XQG
MMFEHH Y>/P[JGG"]FO;1]02?SA+Y+;6^4KM(W<  \8].<Y)JV=#2S\/+:"[N
M<6UJ8\QR% ^ >2!6[5>^_P"0?<_]<F_D: ..\8_\BCI7_79/_1;5PU=SXR_Y
M%+2O^NR?^@-7#4"'V7^I3_KE%_Z+6FZC_P >W_ 7_P#0&IUE_J4_ZY1?^BUI
MNH_\>W_ 7_\ 0&KS%_O7S..7\0XX=!46M_\ 'EIG_7.3_P!&-4HZ"HM;_P"/
M+3/^N<G_ *,:OK,3M$Y\'\3&>&/^1JTO_KY3^=?25A_QZ2_]='_G7S;X8_Y&
MK2_^OE/YU])6'_'I+_UT?^=>/B_XL?1GL4/@E\CR->A_WC_.E3_CZ'_ ?YFD
M7H?]X_SI4_X^A_P'^9K&M_#9C/X673T/TKD-3_X_F_W177GH?I7(:G_Q_-_N
MBGDG\:7H>;4_AOY&SX!_Y'.R^C?RKW*O#? /_(YV7T;^5>Y5V8_^-\CNP'\'
MYA7 ^/O^0I8_]<6_F*[ZN!\??\A2Q_ZXM_,5QQW.N6QR;]/Q%7$^[^)_G5-^
MGXBKB?=_$_SKEQNR./$;(R=?_P"/0?[X_D:YP]*Z/7_^/0?[X_D:YP]*]W*?
M]U1YV(^)>A[C!;1S^![1G,@:.T5E*2,A!V_[)%;>FVT=M81+'O\ F4,2\C.2
M<>I)KYXUCQ#K,%VUI#J=W';K%&HB64A0-@XQ70_#77]7O?&-K:W6I74T!C?]
MW)*2O"G'%<4J,N7F/:C-72/7/$O_ "+.I?\ 7N_\J\K'05ZIXE_Y%G4O^O=_
MY5Y6.@K.(YC[?_6)_O2_^TZFG_X]Y/\ =-0V_P#K$_WI?_:=33_\>\G^Z:\R
MO_'^XX:O\0XZ[_X_KG_KL_\ Z$:[GX4?\AF__P"O<?\ H0KAKO\ X_KG_KL_
M_H1KN?A1_P AF_\ ^O<?^A"OJ\3_ +M]QS8;_>?O/6*IZK_R"[G_ *YFKE4]
M5_Y!=S_US->!5_AR]#WJ?QKU-1/]6OT%6+?J_P"%5T_U:_058M^K_A70MCF>
MY$W^L;ZFDI6_UC?4TE, HHHH S-7O[FU>RM[01">[E,:O*"53"LQ) ()Z8ZC
MK5,>(;2Y\.17-U+%;RW5KY@B+>H[>O-:U[86NHP"&[B$B!MPY((/J".1WJ:*
M*.WA2&%%2-%"JJC  ':@#S[Q7J=E<^&--A@N4DE25"R*<D?(PYKC_,7W_(U[
MI56YU"WM)HX93(9) 658X7D) ZGY0?44 >+VDJ+$H8D8BB'(/4(H--OY%>WP
MI+'#= ?[IKV)]>TV-G$D[IL)5F:%PN0<$9QCBK0O[4R31B9=\*[I!Z#&?Y<U
MSK#KVGM+F+HIRYCYI%O/@?N)?^^#46KV]Q+::>L=O,S(D@8",G&9&-?2"^(=
M+>.%XKDRB8 Q^5&[ELYQP 3V-/76]/D"%)RP;'(C8A<]-QQ\OXXKTZF+E.UT
M12PT:;NF?-/AVVN(/$FFS36\T<:7",S-&0 ,]>E>^V&O:4+64&_@!,C_ ,7O
M74UDZ;_Q[R?]=7_G7#7GSU(M^?Z'=25H2^1X^LJ8/)ZGL?6A)4%R"2<<<X/J
M:]LJH^I6R7,EN6E,D>"^V%V"Y&>2!@<>]3+WHN)$J=U8\I-Q%@_..GI7+:@D
MDEXS)'(RX'(0U[U%K>GS/&BS,&D(5 \3IN)Z8R!^=20ZM87%TUM%=QM.H),>
M><#J<4\'_LLG*.ISRPD91Y;G@^C7EWH^H_;X(3YT,3F,/&2"V.!2S>-?$4]Z
M+N32;4RC)/\ HLF"?4C=7N(U[3&MUG6Z#QMG!5&).#@C &<YJW;7<-VK-"S'
M8VU@R%2#[@@&NBIB/:2YI1-*5#V<>5,Y3P=XP.IZ&)];FM[6[$C+Y84Q_*.G
M!)K*\:ZA:7FHV;VTZ2JL3!BAR <UZ/17/?6YO;2QXD\J8ZGJ.QJVD\6W[_<]
MO>O8JJS:A;P7*V[F4RLNX+'"[\9QD[0<?C65:FJJ5S&I14UJSQ/6V$ML%C#.
M=XX52>QK!,$V/]3)_P!\&OH(:]IQ.//8<XRT3@'G!P2,'FIO[6L/MHLOM48N
M2Q41DX)(&2!ZUVX7$O#T_9I7,)X*,VFV?->M6UQ+J;O';S.I1!E8R1]P>U;W
MPW#:?XSMKB\1X(0C@R2(5 ^4]Z^@J*EUVX\MCI5*SN<WX@UO3)_#VH117T+R
M/ P55;))Q7FXE3 Y/Y&O;*"<#)[5BG8MQN>+03(LBY.,&3J#W\O'\C^52SSQ
M&"0!LDJ<8%>J?VW8^09M\WE;@H;[/)AB6V@#Y>>?2G)K-A)'-(+C"PIYDFY&
M4JH)!X(SU!XKGG04Y\YC*@I2YKGS]<Q2M>7#+%(5,KD'8>1N-=9\/=2M=%U&
M]GU!G@C:$*I,;')W#C %>K+J^GR6\D\=U&\<;B-]GS$,>BX'.>1Q2'6+((&,
MDF3GY!"^\8QG*XR ,CDCN/6O3J8R4Z?LVC.GA(PJ>T3.?@^(VB37/E/'>PK_
M ,]7@.WOZ9/Z=ZT;_7])GTN817\+%T^5<X)S[5MHZR1JZ,&1@"I'<&JNJ_\
M(*N?^N9K@JVY'Z'=2OSKU-1/N+]!5BWZO^%5T_U:_058M^K_ (5NMCG>Y$W^
ML;ZFDI6_UC?4TE, K%\0ZMJ&D1VKV5A;70GG6 ^==-#M9CA>B-D>O]:VJ@NK
M.WO4C6XC#K'(LJ DC#*<@\4 8C^,]+A@5IO.\PY!2*-G.X2>40.,GY^.E,A\
M=Z+/;^;$+QV)4)$+9_,DW D;5QS]UOR-6T\):&EY)=K8CSI'$C,97(W!]_ S
M@?,,X%(_A'0I(/)-B H"@%975EVYQA@<C[QZ'O0 MCXIT_4[IH;%+FX"B-C+
M' =@#J&7GZ,#[5)JFCF_O+>Z$\<?DHR[9$8@Y(YRKKZ5-;:'IMF&%M;>2&9&
M(C=E!**%7H>@  QTHU=))+6/8I91,AD4#)*Y_P <'\* ,V+PW%]MDN)KJ.2.
M5I69%1@6#]027(Q^'XU<T[2HK;37A:Z6XFFWAKDJ,MGCU[# Z]JQ4\-ZBMG8
MHUPTODPE7AD*!!\R':"%!P0I')-2W/A^ZO;U+F*%;$(_F1*&&4<* &(7CGI@
M'I0 L?A>T&H(SZD)$#*PM^ 00#G!!SR3FM1-):VGD_LZZCM8I2N^,0[B-H ^
M4YP.!W!K$\,Z'J.FS$W\,NY]I/DF%HQA #DGY^OI6C9Z9+87%M#%&5474\F0
M20(V.0"?4\?E0!T K)TW_CWD_P"NK_SK6K)TW_CWD_ZZO_.L:GQQ^?Z&U/X'
M\OU+E8\VB-)JL]ZL\8\X*"K1L2N!C@AP/S%;%%,#G(O# AMY8C>JLCH%C=(R
M-K Y#8+')^F*V;2T@M+6*!"A*+LW8&3Z_KVK(U+3[J\U4;&>/;)%(DJ@?*@!
MW 9!&<]JI2^']5>=I%GC)MYFF@:4 M(Q/7Y<!>..E,DG_P"$/B+(4O6";"LB
M!.'.<[NO![5T-M:P6D9C@C"*3DX[GU)JKI*RB.X:1"BO.S(I'0?X5H4AH***
M*!A63?:2;G58;U9XD*1^6$=&.>0<C#KZ>]:U8VN:5/J4MG) ^R2W9G5\_=;:
M0/J,T"92M_#EO%-*LE]$YE61=JJ58[CGG+D<>P'2M?2[**RM%A\X7$R$F28@
M;BQZD^G%8.F^%[HB1[Z4Q.0A"1%"NX%CU*[NI'0BM?2K26W>-7L8H?+BV/,&
M!:1L]1CMWYYS3$C6HHHI%!2,,J1ZBEJGJJ2R:5=) "9&C(4#J: ,7_A'%^PO
M9_;[?[ZRY\ML\.'Y'F=.W&*F3PW$!:(;O!AD9G55XD1FW[,$D@;@#U/0^M4;
MS0;BZ-U]F@98KB-QLE*%,&/:-IP'5N@(/&!4EIHNHV.H^>RBXA@:,0!7&]D"
M2+@YP,C>._('K3)-S4+:*>V4B:.!DE65)" 1N![C(SZ=:H6^CS6TGVJ'48_.
M82'<\1:,*VW[H+Y&-@/7')XI1I=[_8;63-"3)GY=O*;G))W9P< GMU%1W^@[
MIW>TA 3[&80H?'(92JX/&, TAFY!Q!&IF\Y@HS)QEO?CCFJ^J_\ (+N?^N9K
M+T>RO+6_C\X8'E3-(%&%!:0%!QQP-W )QGOU.IJO_(+N?^N9K.K\$O0TI?&O
M4U$_U:_058M^K_A5=/\ 5K]!5BWZO^%="V.9[D3?ZQOJ:2E;_6-]324P"BBB
M@ HHHH **** "BBB@ HHHH *R=-_X]Y/^NK_ ,ZUJQH8=1M@Z+:Q.I=F#&;'
M4^F*PJZ23]3>EK%KT+]%5=VI_P#/C%_X$?\ V-&[4_\ GQB_\"/_ +&E[1=G
M]S_R*Y'W7WHM455W:G_SXQ?^!'_V-&[4_P#GQB_\"/\ [&CVB[/[G_D')YK[
MT6J*J[M3_P"?&+_P(_\ L:-VI_\ /C%_X$?_ &-'M%V?W/\ R#D?=?>BU157
M=J?_ #XQ?^!'_P!C1NU/_GQB_P# C_[&CVB[/[G_ )!R/NOO1#JMS/ L"6_#
M2/C./09Q^/2L&YU6Y6T0VVHO)*VTW)<*%@YY!8*=OI@@^M=#(E_* )-.@8 A
MAF?H1W^[3]VI_P#/C%_X$?\ V-'M%V?W/_(7(^Z^]'(G6M8.\B1@Y0[$)&0H
M7[Y&SH?[V?PK:LKZ\GT>;8SF4!]EUA9(SCI@C;N_(5J;M3_Y\8O_  (_^QHW
M:G_SXQ?^!'_V-'M%V?W/_(7LWW7WHIZ9=7$DMO',YD\RT25B0!M;C/3US^E:
MU4E2_61Y%TZ$.^ S?:.3CI_#3]VI_P#/C%_X$?\ V-'M%V?W/_(:@^Z^]%JB
MJN[4_P#GQB_\"/\ [&C=J?\ SXQ?^!'_ -C1[1=G]S_R'R/NOO1:HJKNU/\
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M:2S+TP1Q@8'7MQ4'C7P_=^(O"DNE6+PI,S(5:=B%PI!Y(!/Z4XVOJ#V/'/\
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M"4S,TDLQS\\H1CT4?W>/NCI38_"EILMS-/.\T2J#)\H)V@ #.W('';&<\YH
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;I1]G_P!O]*** #[/_M_I3TC\O/.<T44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g31397g0512204731096.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31397g0512204731096.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C 'P# 2(  A$! Q$!_\0
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<="8;*SAMXRVXI&@4$^O'T%%%-RD]V"A%;(__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
